USH1531H - Thermophilic DNA polymerase - Google Patents
Thermophilic DNA polymerase Download PDFInfo
- Publication number
- USH1531H USH1531H US08/229,284 US22928494A USH1531H US H1531 H USH1531 H US H1531H US 22928494 A US22928494 A US 22928494A US H1531 H USH1531 H US H1531H
- Authority
- US
- United States
- Prior art keywords
- dna
- dna polymerase
- sequence
- nucleic acid
- polymerase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 title claims abstract description 177
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 title claims abstract description 156
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Chemical group OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 105
- 230000014509 gene expression Effects 0.000 abstract description 36
- 241000588724 Escherichia coli Species 0.000 abstract description 25
- 238000010367 cloning Methods 0.000 abstract description 11
- 108010006785 Taq Polymerase Proteins 0.000 abstract description 3
- 108020004414 DNA Proteins 0.000 description 129
- 150000007523 nucleic acids Chemical class 0.000 description 101
- 210000004027 cell Anatomy 0.000 description 90
- 238000000034 method Methods 0.000 description 90
- 102000039446 nucleic acids Human genes 0.000 description 90
- 108020004707 nucleic acids Proteins 0.000 description 90
- 239000002773 nucleotide Substances 0.000 description 53
- 125000003729 nucleotide group Chemical group 0.000 description 53
- 150000001413 amino acids Chemical class 0.000 description 52
- 102000053602 DNA Human genes 0.000 description 51
- 102000004169 proteins and genes Human genes 0.000 description 49
- 235000018102 proteins Nutrition 0.000 description 47
- 239000013615 primer Substances 0.000 description 43
- 108090000765 processed proteins & peptides Proteins 0.000 description 43
- 108091028043 Nucleic acid sequence Proteins 0.000 description 41
- 238000003752 polymerase chain reaction Methods 0.000 description 41
- 239000012634 fragment Substances 0.000 description 40
- 230000000694 effects Effects 0.000 description 38
- 239000013598 vector Substances 0.000 description 34
- 235000001014 amino acid Nutrition 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 31
- 102000004196 processed proteins & peptides Human genes 0.000 description 30
- 239000000523 sample Substances 0.000 description 29
- 241000205236 Desulfurococcus Species 0.000 description 25
- 229920001184 polypeptide Polymers 0.000 description 23
- 230000000295 complement effect Effects 0.000 description 19
- 230000035772 mutation Effects 0.000 description 19
- 239000013612 plasmid Substances 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- 229940088598 enzyme Drugs 0.000 description 16
- 108060002716 Exonuclease Proteins 0.000 description 15
- 102000013165 exonuclease Human genes 0.000 description 15
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 14
- 238000009396 hybridization Methods 0.000 description 14
- 239000002853 nucleic acid probe Substances 0.000 description 14
- 238000006467 substitution reaction Methods 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 241000894007 species Species 0.000 description 12
- 239000001226 triphosphate Substances 0.000 description 12
- 235000011178 triphosphate Nutrition 0.000 description 12
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 12
- 108020004705 Codon Proteins 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 239000013611 chromosomal DNA Substances 0.000 description 11
- 239000013604 expression vector Substances 0.000 description 11
- 238000012163 sequencing technique Methods 0.000 description 11
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- 238000012217 deletion Methods 0.000 description 10
- 230000037430 deletion Effects 0.000 description 10
- 210000004408 hybridoma Anatomy 0.000 description 10
- 238000003780 insertion Methods 0.000 description 10
- 230000037431 insertion Effects 0.000 description 10
- 238000002372 labelling Methods 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 108020004635 Complementary DNA Proteins 0.000 description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
- 238000010804 cDNA synthesis Methods 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 230000002441 reversible effect Effects 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 238000001712 DNA sequencing Methods 0.000 description 8
- 108091092195 Intron Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 238000010369 molecular cloning Methods 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 238000002741 site-directed mutagenesis Methods 0.000 description 8
- 230000002103 transcriptional effect Effects 0.000 description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 7
- 239000005549 deoxyribonucleoside Substances 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 230000000977 initiatory effect Effects 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 239000000020 Nitrocellulose Substances 0.000 description 6
- 108020004682 Single-Stranded DNA Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 229920001220 nitrocellulos Polymers 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- 108091081024 Start codon Proteins 0.000 description 5
- 239000004098 Tetracycline Substances 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 238000000246 agarose gel electrophoresis Methods 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000002523 gelfiltration Methods 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229960002180 tetracycline Drugs 0.000 description 5
- 229930101283 tetracycline Natural products 0.000 description 5
- 235000019364 tetracycline Nutrition 0.000 description 5
- 150000003522 tetracyclines Chemical class 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 4
- 230000004544 DNA amplification Effects 0.000 description 4
- 241000701959 Escherichia virus Lambda Species 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 238000002105 Southern blotting Methods 0.000 description 4
- 241000187747 Streptomyces Species 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 4
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 4
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 239000013600 plasmid vector Substances 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 210000001236 prokaryotic cell Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 108010017826 DNA Polymerase I Proteins 0.000 description 3
- 102000004594 DNA Polymerase I Human genes 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000589500 Thermus aquaticus Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000013599 cloning vector Substances 0.000 description 3
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 3
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 3
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 108010078347 pregnancy-associated murine protein 1 Proteins 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- OAKPWEUQDVLTCN-NKWVEPMBSA-N 2',3'-Dideoxyadenosine-5-triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO[P@@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)O1 OAKPWEUQDVLTCN-NKWVEPMBSA-N 0.000 description 2
- 229920000178 Acrylic resin Polymers 0.000 description 2
- 239000004925 Acrylic resin Substances 0.000 description 2
- 241000203069 Archaea Species 0.000 description 2
- 241000304886 Bacilli Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- HDRRAMINWIWTNU-NTSWFWBYSA-N [[(2s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HDRRAMINWIWTNU-NTSWFWBYSA-N 0.000 description 2
- ARLKCWCREKRROD-POYBYMJQSA-N [[(2s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 ARLKCWCREKRROD-POYBYMJQSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- URGJWIFLBWJRMF-JGVFFNPUSA-N ddTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 URGJWIFLBWJRMF-JGVFFNPUSA-N 0.000 description 2
- -1 e.g. Chemical group 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002414 glycolytic effect Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 238000011005 laboratory method Methods 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 150000002972 pentoses Chemical group 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000002987 primer (paints) Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- 102000000662 3'-5' exonuclease domains Human genes 0.000 description 1
- 108050008023 3'-5' exonuclease domains Proteins 0.000 description 1
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical group NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- 241000203809 Actinomycetales Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- CXISPYVYMQWFLE-VKHMYHEASA-N Ala-Gly Chemical compound C[C@H]([NH3+])C(=O)NCC([O-])=O CXISPYVYMQWFLE-VKHMYHEASA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- HCAUEJAQCXVQQM-ACZMJKKPSA-N Asn-Glu-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HCAUEJAQCXVQQM-ACZMJKKPSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- ZGERHCJBLPQPGV-ACZMJKKPSA-N Cys-Ser-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N ZGERHCJBLPQPGV-ACZMJKKPSA-N 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 101100364969 Dictyostelium discoideum scai gene Proteins 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 108700010895 Drosophila ADH Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241001302160 Escherichia coli str. K-12 substr. DH10B Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101150082479 GAL gene Proteins 0.000 description 1
- 108010001515 Galectin 4 Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 1
- FTIJVMLAGRAYMJ-MNXVOIDGSA-N Gln-Ile-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(N)=O FTIJVMLAGRAYMJ-MNXVOIDGSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- CBEUFCJRFNZMCU-SRVKXCTJSA-N Glu-Met-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O CBEUFCJRFNZMCU-SRVKXCTJSA-N 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- RXVOMIADLXPJGW-GUBZILKMSA-N His-Asp-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O RXVOMIADLXPJGW-GUBZILKMSA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- RENBRDSDKPSRIH-HJWJTTGWSA-N Ile-Phe-Met Chemical compound N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)O RENBRDSDKPSRIH-HJWJTTGWSA-N 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical class CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
- 101100364971 Mus musculus Scai gene Proteins 0.000 description 1
- 101100202339 Mus musculus Slc6a13 gene Proteins 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 101100005280 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cat-3 gene Proteins 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- BQMFWUKNOCJDNV-HJWJTTGWSA-N Phe-Val-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BQMFWUKNOCJDNV-HJWJTTGWSA-N 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010059820 Polygalacturonase Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- FDINZVJXLPILKV-DCAQKATOSA-N Pro-His-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(O)=O FDINZVJXLPILKV-DCAQKATOSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 101100202330 Rattus norvegicus Slc6a11 gene Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- QFBNNYNWKYKVJO-DCAQKATOSA-N Ser-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CCCN=C(N)N QFBNNYNWKYKVJO-DCAQKATOSA-N 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 241000205188 Thermococcus Species 0.000 description 1
- 241000204652 Thermotoga Species 0.000 description 1
- GQPQJNMVELPZNQ-GBALPHGKSA-N Thr-Ser-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N)O GQPQJNMVELPZNQ-GBALPHGKSA-N 0.000 description 1
- 240000001085 Trapa natans Species 0.000 description 1
- LUMQYLVYUIRHHU-YJRXYDGGSA-N Tyr-Ser-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LUMQYLVYUIRHHU-YJRXYDGGSA-N 0.000 description 1
- FZADUTOCSFDBRV-RNXOBYDBSA-N Tyr-Tyr-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=C(O)C=C1 FZADUTOCSFDBRV-RNXOBYDBSA-N 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- DAVNYIUELQBTAP-XUXIUFHCSA-N Val-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N DAVNYIUELQBTAP-XUXIUFHCSA-N 0.000 description 1
- GVJUTBOZZBTBIG-AVGNSLFASA-N Val-Lys-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N GVJUTBOZZBTBIG-AVGNSLFASA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- PXHHTOSRELKWOE-MXWQNOQOSA-N [hydroxy-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl] phosphono hydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=S)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 PXHHTOSRELKWOE-MXWQNOQOSA-N 0.000 description 1
- ZXZIQGYRHQJWSY-NKWVEPMBSA-N [hydroxy-[[(2s,5r)-5-(6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy]phosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)O)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 ZXZIQGYRHQJWSY-NKWVEPMBSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000002299 affinity electrophoresis Methods 0.000 description 1
- 239000007801 affinity label Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- UFJPAQSLHAGEBL-RRKCRQDMSA-N dITP Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(N=CNC2=O)=C2N=C1 UFJPAQSLHAGEBL-RRKCRQDMSA-N 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 108010093305 exopolygalacturonase Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 108010042598 glutamyl-aspartyl-glycine Proteins 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229940059442 hemicellulase Drugs 0.000 description 1
- 108010002430 hemicellulase Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000012135 ice-cold extraction buffer Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 229950003188 isovaleryl diethylamide Drugs 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 101150109249 lacI gene Proteins 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 108010058731 nopaline synthase Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 125000000405 phenylalanyl group Chemical group 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 101150035983 str1 gene Proteins 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1252—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
Definitions
- the present invention relates to a substantially pure thermostable DNA polymerase.
- the DNA polymerase of the present invention is a Desulfurococcus strain Tok12-S1 DNA polymerase having a molecular weight of about 95 kilodaltons.
- the present invention also relates to cloning and expression of the this DNA polymerase in E. coli, to DNA molecules containing the cloned gene, and to hosts which express the gene.
- DNA polymerases synthesize the formation of DNA molecules which are complementary to a DNA template. Upon binding to a primer terminus of a DNA template, polymerases synthesize DNA in the 5' to 3' direction, successively adding nucleotides to the 3'-hydroxyl group of the growing strand. Thus, in the presence of deoxyribonucleoside triphosphates (dNTPs) and a primed template, a new DNA molecule, complementary to the single stranded DNA template, can by synthesized.
- dNTPs deoxyribonucleoside triphosphates
- a number of DNA polymerases have been isolated from mesophilic microorganisms such as E. coli. A number of these mesophilic DNA polymerases have also been cloned. Lin et al. cloned and expressed T4 DNA polymerase in E. coli (Proc. Natl. Acad. Sci. USA 84:7000-7004 (1987)). Tabor et al. (U.S. Pat. No. 4,795,699) describes a cloned T7 DNA polymerase, while Minkley et al. (J. Biol. Chem. 259 (16):10386-10392 (1984)) and Chatterjee (U.S. Pat. No. 5,047,342) described cloning of E. coli DNA polymerase I and T5 DNA polymerase, respectively.
- Gelland et al. (U.S. Pat. No. 4,889,818) cloned a gene encoding a thermostable DNA polymerase from Thermus aquaticus. The molecular weight of this protein was found to be about 86,000 to 90,000 daltons.
- Thermophilic bacteria other than Thermus aquaticus, have been isolated and a number of thermostable enzymes have been isolated from these organisms.
- Bragger et al. Appl. Microbiol. Biotechnol. 31:556-561 (1989) screened thirty-six thermophilic archaebacteria and nine extremely thermophilic eubacteria for extracellular amylase, protease, hemicellulase (xylanase), cellulase, pectinase and lipase activities.
- DNA polymerases have been isolated from thermophilic bacteria including Thermotoga (Simpson et al., Biochem. Cell. Biol. 86:1292-1296 (1990)); Bacillus stearothermophilus (Stenesh et al., Biochim. Biochys. Acta 272:156-166 (1972); and Kaboev et al., J. Bacteriol. 145:21-26 (1981)); and several archaebacterial species (Rossi et al., System. Appl. Microbiol. 7:337-341 (1986); Klimczak et al., Biochemistry 25:4850-4855 (1986); and Elie et al., Eur. J. Biochem.
- the present invention is directed to a DNA polymerase comprising amino acids 99 to 135 set forth in SEQ ID NO:2 or comprising amino acids 98 to 136 set forth in SEQ ID NO:2. More specifically, the DNA polymerase of the invention is isolated from Desulfurococcus strain Tok12-S1.
- the DNA polymerase of the present invention is extremely thermostable, showing no loss of activity after 90 minutes at 95° C.
- the DNA polymerase possesses a 3'-5' exonuclease activity.
- the DNA polymerase of the present invention has the ability to remove incorrectly incorporated nucleotides, an ability that the Thermus aquaticus DNA polymerase does not have.
- the present invention is also directed to cloning a gene encoding the above-described DNA polymerase.
- the invention also provides a nucleic acid probe molecule for specifically detecting the presence of the above-described DNA polymerase nucleic acid in a sample comprising a nucleic acid molecule sufficient to specifically detect by hybridization the presence of the above-described DNA polymerase nucleic acid in the sample.
- the invention further provides a recombinant nucleic acid molecule comprising, 5' to 3', a promoter effective to initiate transcription in a host cell and the above-described isolated nucleic acid molecule.
- the invention also provides a cell that contains the above-described recombinant nucleic acid molecule.
- the invention further provides a non-human organism comprising a cell that contains the above-described recombinant nucleic acid molecule.
- the invention also provides a method of producing the above-described DNA polymerase, the method comprising:
- the invention further provides a method of synthesizing a double-stranded DNA molecule comprising:
- the invention also provides a method for purifying thermostable proteins larger than 50 kd in size in a sample, wherein the proteins are expressed in a therophilic host, comprising:
- thermostable proteins by gel filtration.
- isolated nucleic acid molecule refers to a polymer of nucleotides, and includes but is not limited to DNA and RNA.
- a DNA segment refers to a molecule comprising a linear stretch of nucleotides wherein the nucleotides are present in a sequence that may encode, through the genetic code, a molecule comprising a linear sequence of amino acid residues that is referred to as a protein, a protein fragment or a polypeptide.
- Promoter A DNA sequence generally described as the 5' region of a gene, located proximal to the start codon. At the promoter region, transcription of an adjacent gene(s) is initiated.
- Gene A DNA sequence that contains information necessary for expression of a polypeptide or protein. It includes the promoter and the structural gene as well as other sequences involved in expression of the protein.
- cDNA Complementary DNA
- mRNA messenger RNA
- Structural Gene A DNA sequence that is transcribed into mRNA that is then translated into a sequence of amino acids characteristic of a specific polypeptide.
- restriction endonuclease also restriction enzyme
- a restriction endonuclease is an enzyme that has the capacity to recognize a specific base sequence (usually 4, 5, or 6 base pairs in length) in a DNA molecule, and to cleave the DNA molecule at every place where this sequence appears.
- EcoRI recognizes the base sequence GAATTC.
- Restriction Fragment The DNA molecules produced by digestion with a restriction endonuclease are referred to as restriction fragments. Any given genome may be digested by a particular restriction endonuclease into a discrete set of restriction fragments.
- the DNA fragments fractionated by agarose gel electrophoresis can be visualized directly by a staining procedure if the number of fragments included in the pattern is small.
- the DNA fragments of genomes can be visualized successfully.
- most genomes, including the human genome contain far too many DNA sequences to produce a simple pattern of restriction fragments.
- the human genome is digested into approximately 1,000,000 different DNA fragments by EcoRI.
- a methodology referred to as the Southern hybridization procedure can be applied.
- Southern Transfer Procedure The purpose of the Southern transfer procedure (also referred to as blotting) is to physically transfer DNA fractionated by agarose gel electrophoresis onto a nitrocellulose filter paper or another appropriate surface or method, while retaining the relative positions of DNA fragments resulting from the fractionation procedure.
- the methodology used to accomplish the transfer from agarose gel to nitrocellulose involves drawing the DNA from the gel into the nitrocellulose paper by capillary action.
- Oligonucleotide refers to a synthetic or natural molecule comprising a covalently linked sequence of nucleotides which are joined by a phosphodiester bond between the 3' position of the pentose of one nucleotide and the 5' position of the pentose of the adjacent nucleotide.
- nucleotide refers to a base-sugar-phosphate combination. Nucleotides are monomeric units of a nucleic acid sequence (DNA and RNA).
- nucleotide includes deoxyribonucleoside triphosphates such as dATP, dCTP, dUTP, dGTP, dTTP, or derivatives thereof. Such derivatives include, for example, dITP, ⁇ SdATP and 7-deaza-dGTP.
- nucleotide as used herein also refers to dideoxyribonucleoside triphosphates (ddNTPs) and their derivatives.
- ddATP dideoxyribonucleoside triphosphates
- ddCTP dideoxyribonucleoside triphosphates
- ddGTP dideoxyribonucleoside triphosphates
- ddTTP dideoxyribonucleoside triphosphates
- Detectable labels include, for example, radioactive isotopes, fluorescent labels, chemiluminescent labels, bioluminescent labels and enzyme labels.
- Hybridization Probe To visualize a particular DNA sequence in the Southern hybridization procedure, a labeled DNA molecule or hybridization probe is reacted to the fractionated DNA bound to the nitrocellulose filter. The areas on the filter that carry DNA sequences complementary to the labeled DNA probe become labeled themselves as a consequence of the reannealing reaction. The areas of the filter that exhibit such labeling are visualized.
- the hybridization probe is generally produced by molecular cloning of a specific DNA sequence.
- Nucleic Acid Hybridization depends on the principle that two single-stranded nucleic acid molecules that have complementary base sequences will reform the thermodynamically favored double-stranded structure if they are mixed under the proper conditions. The double-stranded structure will be formed between two complementary single-stranded nucleic acids even if one is immobilized on a nitrocellulose filter. In the Southern hybridization procedure, the latter situation occurs. As noted previously, the DNA of the individual to be tested is digested with a restriction endonuclease, fractionated by agarose gel electrophoresis, converted to the single-stranded form, and transferred to nitrocellulose paper, making it available for reannealing to the hybridization probe.
- Amplification refers to any in vitro method for increasing the number of copies of a nucleotide sequence with the use of a DNA polymerase. Nucleic acid amplification results in the incorporation of nucleotides into a DNA molecule or primer thereby forming a new DNA molecule complementary to a DNA template. The formed DNA molecule and its template can be used as templates to synthesize additional DNA molecules.
- one amplification reaction may consist of many rounds of DNA replication.
- DNA amplification reactions include, for example, polymerase chain reactions (PCR).
- PCR polymerase chain reactions
- One PCR reaction may consist of 30 to 100 "cycles" of denaturation and synthesis of a DNA molecule.
- Primer refers to a single-stranded oligonucleotide that is extended by covalent bonding of nucleotide monomers during amplification or polymerization of a DNA molecule.
- Amplification Primer An oligonucleotide which is capable of annealing adjacent to a target sequence and serving as an initiation point for DNA synthesis when placed under conditions in which synthesis of a primer extension product which is complementary to a nucleic acid strand is initiated.
- template refers to a double-stranded or single-stranded DNA molecule which is to be amplified, synthesized or sequenced.
- template denaturation of its strands to form a first and a second strand is performed before these molecules may be amplified, synthesized or sequenced.
- a primer, complementary to a portion of a DNA template is hybridized under appropriate conditions and the DNA polymerase of the invention may then synthesize a DNA molecule complementary to the template or a portion thereof.
- the newly synthesized DNA molecule may be equal or shorter in length than the original DNA template. Mismatch incorporation during the synthesis or extension of the newly synthesized DNA molecule may result in one or a number of mismatched base pairs. Thus, the synthesized DNA molecule need not be exactly complementary to the DNA template.
- Vector A plasmid or phage DNA or other DNA sequence into which DNA may be inserted to be cloned.
- the vector may replicate autonomously in a host cell, and may be further characterized by one or a small number of endonuclease recognition sites at which such DNA sequences may be cut in a determinable fashion and into which DNA may be inserted.
- the vector may further contain a marker suitable for use in the identification of cells transformed with the vector. Markers, for example, are tetracycline resistance or ampicillin resistance. The words "cloning vehicle” are sometimes used for "vector.”
- Operably linked means that the promoter controls the initiation of the expression of the polypeptide encoded by the structural gene.
- Expression is the process by which a polypeptide is produced from a structural gene. It involves transcription of the gene into mRNA, and the translation of such mRNA into polypeptide(s).
- Expression Vector A vector or vehicle similar to a cloning vector but which is capable of expressing a gene which has been cloned into it, after transformation into a host.
- the cloned gene is usually placed under the control of (i.e., operably linked to) certain control sequences such as promoter sequences.
- Expression control sequences will vary depending on whether the vector is designed to express the operably linked gene in a prokaryotic or eukaryotic host and may additionally contain transcriptional elements such as enhancer elements, termination sequences, tissue-specificity elements, and/or translational initiation and termination sites.
- a “functional derivative” of a sequence is a molecule that possesses a biological activity (either functional or structural) that is substantially similar to a biological activity of the protein or nucleic acid sequence.
- a functional derivative of a protein may or may not contain post-translational modifications such as covalently linked carbohydrate, depending on the necessity of such modifications for the performance of a specific function.
- the term “functional derivative” is intended to include the “fragments,” “segments,” “variants,” “analogs,” or “chemical derivatives” of a molecule.
- a molecule is said to be a "chemical derivative" of another molecule when it contains additional chemical moieties not normally a part of the molecule. Such moieties may improve the molecule's solubility, absorption, biological half life, and the like. The moleties may alternatively decrease the toxicity of the molecule, eliminate or attenuate any undesirable side effect of the molecule, and the like. Moieties capable of mediating such effects are disclosed in Remington's Pharmaceutical Sciences (1980). Procedures for coupling such moieties to a molecule are well known in the art.
- Fragment of a molecule such as a protein or nucleic acid is meant to refer to any portion of the amino acid or nucleotide genetic sequence.
- variants of a protein or nucleic acid are meant to refer to a molecule substantially similar in structure and biological activity to either the protein or nucleic acid, or to a fragment thereof. Thus, provided that two molecules possess a common activity and may substitute for each other, they are considered variants as that term is used herein even if the composition or secondary, tertiary, or quaternary structure of one of the molecules is not identical to that found in the other, or if the amino acid or nucleotide sequence is not identical.
- Analog of a protein or genetic sequence is meant to refer to a protein or genetic sequence substantially similar in function to a protein or genetic sequence described herein.
- Allele is an alternative form of a gene occupying a given locus on the chromosome.
- Mutation is any detectable change in the genetic material which may be transmitted to daughter cells and possibly even to succeeding generations giving rise to mutant cells or mutant individuals. If the descendants of a mutant cell give rise only to somatic cells in multicellular organisms, a mutant spot or area of cells arises. Mutations in the germ line of sexually reproducing organisms may be transmitted by the gametes to the next generation resulting in an individual with the new mutant condition in both its somatic and germ cells.
- a mutation may be any (or a combination of) detectable, unnatural change affecting the chemical or physical constitution, mutability, replication, phenotypic function, or recombination of one or more deoxyribonucleotides; nucleotides may be added, deleted, substituted for, inverted, or transposed to new positions with and without inversion. Mutations may occur spontaneously and can be induced experimentally by application of mutagens. A mutant variation of a nucleic acid molecule results from a mutation. A mutant polypeptide may result from a mutant nucleic acid molecule.
- Species is a group of actually or potentially interbreeding natural populations.
- a species variation within a nucleic acid molecule or protein is a change in the nucleic acid or amino acid sequence that occurs among species and may be determined by DNA sequencing of the molecule in question.
- Recombinant host Any prokaryotic or eukaryotic or microorganism which contains the desired cloned genes on an expression vector, cloning vector or any DNA molecule.
- the term "recombinant host” is also meant to include those host cells which have been genetically engineered to contain the desired gene on the host chromosome or genome.
- the DNA molecule may contain, but is not limited to, a structural gene, a promoter and/or an origin of replication.
- substantially pure means that the desired purified protein or nucleic acid is essentially free from contaminating cellular contaminants which are associated with the desired protein or nucleic acid in nature as evidenced, for example, as one band on an electrophorectic gel. Contaminating cellular components may include, but are not limited to, phosphatases, exonucleases, endonucleases or undesirable DNA polymerase enzymes.
- thermostable refers to a DNA polymerase which is resistant to inactivation by heat.
- DNA polymerases synthesize the formation of a DNA molecule complementary to a single-stranded DNA template by extending a primer in the 5' to 3' direction. This activity for mesophilic DNA polymerases may be inactivated by heat treatment. For example, T5 DNA polymerase activity is totally inactivated by exposing the enzyme to a temperature of 90° C. for 30 seconds.
- a thermostable DNA polymerase activity is more resistant to heat inactivation than a mesophilic DNA polymerase.
- thermostable DNA polymerase does not mean to refer to an enzyme which is totally resistant to heat inactivation and thus heat treatment may reduce the DNA polymerase activity to some extent.
- a thermostable DNA polymerase typically will also have a higher optimum temperature than mesophilic DNA polymerases. Preferably, the thermostable DNA polymerase will lose substantially no activity after 60 minutes at 95° C.
- I Isolated nucleic acid molecules coding for the DNA polymerase, and fragments thereof.
- Kits containing the DNA polymerase
- V A nucleic acid probe for the detection of the DNA polymerase nucleic acid.
- DNA constructs comprising a DNA polymerase nucleic acid molecule and cells containing these constructs.
- the present invention relates to an isolated nucleic acid molecule coding for a DNA polymerase comprising amino acids 99 to 135 set forth in SEQ ID NO:2, or at least 39 contiguous amino acids thereof (preferably, at least 50, 70, or 100 contiguous amino acids thereof).
- the nucleic acid molecule codes for a DNA polymerase comprising amino acids 98 to 136 set forth in SEQ ID NO:2.
- the isolated nucleic acid molecule comprises the sequence set forth in SEQ ID NO:1; allelic, mutant or species variation thereof, or at least 20 contiguous nucleotides thereof (preferably at least 25, 30, 35, 40, or 50 contiguous nucleotides thereof).
- the isolated nucleic acid molecule encodes the amino acid sequence set forth in SEQ ID NO:2, or mutant or species variation thereof, or at least 39 contiguous amino acids thereof (preferably, at least 50, 70, or 100 contiguous amino acids thereof).
- the nucleic acid molecule is greater than 80% homologous to the sequences set forth in SEQ ID NO:1; allelic, mutant or species variation thereof, or at least 20 contiguous nucleotides thereof (preferably at least 25, 30, 35, 40, or 50 contiguous nucleotides thereof). In another preferred embodiment, the nucleic acid molecule is greater than 90% homologous. In yet another preferred embodiment, the nucleic acid molecule is greater than 95% homologous. Homologous nucleic acid molecules may be identified using hybrididation conditions (prefereably, stringent hybridization conditions) as described in Sambrook et al., In: Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.(1989).
- the DNA polymerase and nucleic acid of the invention can be isolated from any strain of Desulfurococcus which produces a DNA polymerase having the molecular weight of 95 kilodaltons.
- the preferred strain to isolate the gene encoding the DNA polymerase of the present invention is Desulfurococcus strain Tok12-S1 obtained from Pacific Enzymes Ltd., Aukland, New Zealand (now, UniServices).
- nucleic acid sequences depicted in SEQ ID NO: 1 can be altered by substitutions, additions or deletions that provide for functionally equivalent molecules. Due to the degeneracy of nucleotide coding sequences, other DNA sequences which encode substantially the same amino acid sequence as depicted in SEQ ID NO:2 may be used in the practice of the present invention. These include but are not limited to nucleotide sequences comprising all or portions of the DNA polymerase nucleic acid depicted in SEQ ID NO: 1 which are altered by the substitution of different codons that encode a functionally equivalent amino acid residue within the sequence, thus producing a silent change.
- nucleic acid sequence affords an opportunity to promote secretion and/or processing of heterologous proteins encoded by foreign nucleic acid sequences fused thereto. All variations of the nucleotide sequence of the DNA polymerase genes and fragments thereof permitted by the genetic code are, therefore, included in this invention.
- nucleic acid sequence may comprise a nucleotide sequence which results from the addition, deletion or substitution of at least one nucleotide to the 5'-end and/or the 3'-end of the nucleic acid formula shown in SEQ ID NO:1 or a derivative thereof.
- Any nucleotide or polynucleotide may be used in this regard, provided that its addition, deletion or substitution does not alter the amino acid sequence of SEQ ID NO:2 which is encoded by the nucleotide sequence.
- the present invention is intended to include any nucleic acid sequence resulting from the addition of ATG as an initiation codon at the 5'-end of the present nucleic acid sequence or its derivative, or from the addition of TAA, TAG or TGA as a termination codon at the 3'-end of the inventive nucleotide sequence or its derivative.
- the nucleic acid molecule of the present invention may, as necessary, have restriction endonuclease recognition sites added to its 5'-end and/or 3'-end.
- codons or to substitute one or more codons by codons other than degenerate codons to produce a structurally modified polymerase, but one which has substantially the same utility or activity of the polymerase produced by the unmodified nucleic acid molecule.
- the two polymerases are functionally equivalent, as are the two nucleic acid molecules which give rise to their production, even though the differences between the nucleic acid molecules are not related to degeneracy of the genetic code.
- nucleic acid molecules coding for polypeptides having amino acid sequences corresponding to the above-described DNA polymerase are provided.
- the nucleic acid molecule may be isolated from a biological sample containing RNA or DNA.
- the nucleic acid molecule may be isolated from a biological sample containing RNA using the techniques of cDNA cloning and subtractive hybridization.
- the nucleic acid molecule may also be isolated from a cDNA library using a homologous probe.
- the nucleic acid molecule may be isolated from a biological sample containing genomic DNA or from a genomic library using techniques well known in the art. The method of obtaining the biological sample will vary depending upon the nature of the sample.
- the isolated nucleic acid molecule is also intended to include allelic variations, so long as the sequence is a functional derivative of the DNA polymerase gene.
- allelic variations so long as the sequence is a functional derivative of the DNA polymerase gene.
- an allele does not encode the identical sequence to that of SEQ ID NO: 1, it can be isolated and identified as the DNA polymerase using the same techniques used herein, and especially PCR techniques to amplify the appropriate gene with primers based on the sequences disclosed herein.
- Desulfurococcus will also contain genes similar to the Desulfurococcus strain Tok12-S1 DNA polymerase gene (for example Thermococcus strain AN1 (DSM 2770)).
- the invention is intended to include, but not be limited to, the DNA polymerase nucleic acid molecules isolated from the above-described organisms.
- Isolated nucleic acid molecules of the present invention are also meant to include those chemically synthesized.
- a nucleic acid molecule with the nucleotide sequence which codes for the expression product of the DNA polymerase gene may be designed and, if necessary, divided into appropriate smaller fragments. Then an oligomer which corresponds to the nucleic acid molecule, or to each of the divided fragments, may be synthesized.
- Such synthetic oligonucleotides may be prepared, for example, by the triester method of Matteucci et al., J. Am. Chem. Soc. 103:3185-3191 (1981) or by using an automated DNA synthesizer.
- An oligonucleotide may be derived synthetically or by cloning. If necessary, the 5'-ends of the oligomers may be phosphorylated using T4 polynucleotide kinase. Kinasing of single strands prior to annealing or for labeling may be achieved using an excess of the enzyme. If kinasing is for the labeling of probe, the ATP may contain high specific activity radioisotopes. Then, the DNA oligomer may be subjected to annealing and ligation with T4 ligase or the like.
- the present invention relates to a substantially pure DNA polymerase comprising amino acids 99 to 135 set forth in SEQ ID NO:2, or a fragment or derivative thereof, or at least 39 contiguous amino acids thereof (preferably, at least 50, 70, or 100 contiguous amino acids thereof), or a functional derivative thereof.
- the polymerase comprises amino acids 98 to 136 set forth in SEQ ID NO:2.
- the polypeptide has the amino acid sequence set forth in SEQ ID NO:2, or mutant or species variation thereof, or at least 39 contiguous amino acids thereof (preferably, at least 50, 70, or 100 contiguous amino acids thereof).
- Amino acid sequence variants of the DNA polymerase can be prepared by mutations in the DNA. Such variants include, for example, deletions from, or insertions or substitutions of, residues within the amino acid sequence shown in SEQ ID NO:2. Any combination of deletion, insertion, and substitution may also be made to arrive at the final construct, provided that the final construct possesses the desired activity. Obviously, the mutations that will be made in the DNA encoding the variant must not place the sequence out of reading frame and preferably will not create complementary regions that could produce secondary mRNA structure (see EP Patent Application Publication No. 75,444).
- the mutation per se need not be predetermined.
- random mutagenesis may be conducted at the target codon or region and the expressed DNA polymerase variants screened for the optimal combination of desired activity.
- Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known and include, for example, site-specific mutagenesis.
- Preparation of a DNA polymerase variant in accordance herewith is preferably achieved by site-specific mutagenesis of DNA that encodes an earlier prepared variant or a nonvariant version of the protein.
- Site-specific mutagenesis allows the production of DNA polymerase variants through the use of specific oligonucleotide sequences that encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on both sides of the deletion junction being traversed.
- a primer of about 20 to 25 nucleotides in length is preferred, with about 5 to 10 residues on both sides of the junction of the sequence being altered.
- the technique of site-specific mutagenesis is well known in the art, as exemplified by publications such as Adelman et al., DNA 2:183 (1983).
- the site-specific mutagenesis technique typically employs a phage vector that exists in both a single-stranded and double-stranded form.
- Typical vectors useful in site-directed mutagenesis include vectors such as the M13 phage, for example, as disclosed by Messing et al., Third Cleveland Symposium on Macromolecules and Recombinant DNA, Editor A. Walton, Elsevier, Amsterdam (1981). These phage are readily commercially available and their use is generally well known to those skilled in the art.
- plasmid vectors that contain a single-stranded phage origin of replication may be employed to obtain single-stranded DNA.
- site-directed mutagenesis in accordance herewith is performed by the technique described by Kunkel, Proc. Natl. Acad. Sci. 82:488-492 (1985).
- An oligonucleotide primer bearing the desired mutated sequence is prepared, generally synthetically, for example, by the method of Crea et al., Proc. Natl. Acad. Sci. (USA) 75:5765 (1978). This primer is then annealed with the single-stranded DNA obtained from E. coli CJ236 (Kunkel, et al., Proc. Natl. Acad. Sci.
- This heteroduplex vector is then used to transform appropriate cells such as DH5 ⁇ F'I q , cells (Life Tech. Inc.) and clones are selected that include recombinant vectors bearing the mutated sequence arrangement.
- the mutated protein region may be removed and placed in an appropriate vector for protein production, generally an expression vector of the type that may be employed for transformation of an appropriate host.
- an appropriate vector for protein production generally an expression vector of the type that may be employed for transformation of an appropriate host.
- a PCR directed mutagenesis can also be performed to obtain similar clones.
- Amino acid sequence deletions generally range from about 1 to 30 residues, more preferably 1 to 10 residues, and typically are contiguous.
- Amino acid sequence insertions include amino and/or carboxyl-terminal fusions of from one residue to polypeptides of essentially unrestricted length, as well as intrasequence insertions of single or multiple amino acid residues.
- lntrasequence insertions i.e., insertions within the complete DNA polymerase sequence
- An example of a terminal insertion includes a fusion of a signal sequence, whether heterologous or homologous to the host cell, to the N-terminus of the DNA polymerase to facilitate the secretion of DNA polymerase from recombinant hosts.
- the third group of variants are those in which at least one amino acid residue in the DNA polymerase molecule, and preferably, only one, has been removed and a different residue inserted in its place. Such substitutions preferably are made in accordance with the following Table 1 when it is desired to modulate finely the characteristics of the DNA polymerase.
- Substantial changes in functional or immunological identity are made by selecting substitutions that are less conservative than those in Table 1, i.e., selecting residues that differ more significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.
- substitutions that in general are expected to cause the above changes are those in which (a) glycine and/or proline is substituted by another amino acid or is deleted or inserted; (b)a hydrophilic residue, e.g., seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g., leucyl, isoleucyl, phenylalanyl, valyl, or alanyl; (c) a cysteine residue is substituted for (or by) any other residue; (d) a residue having an electropositive side chain, e.g., lysyl, arginyl, or histidyl, is substituted for (or by) a residue having an electronegative charge, e.g., glutamyl or aspartyl; or (e) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) one not having such a side
- a variant typically is made by site-specific mutagenesis of the native DNA polymerase encoding-nucleic acid, expression of the variant nucleic acid in recombinant cell culture and, optionally, purification from the cell culture, for example, by immunoaffinity adsorption on a column (to absorb the variant by binding it to at least one remaining immune epitope).
- the activity of the cell lysate or purified DNA polymerase molecule variant is then screened in a suitable screening assay for the desired characteristic. For example, a change in the immunological character of the DNA polymerase molecule, such as affinity for a given antibody, is measured by a competitive type immunoassay. Changes in immunomodulation activity are measured by the appropriate assay. Modifications of such protein properties as redox or thermal stability, hydrophobicity, susceptibility to proteolytic degradation or the tendency to aggregate with carriers or into multimers are assayed by methods well known to the ordinarily skilled artisan.
- the peptide is purified from cells which naturally produce the peptide.
- the above-described isolated nucleic acid fragments could be used to expressed the DNA polymerase in any organism.
- the samples of the present invention include cells, protein extracts or membrane extracts of cells, or biological fluids. The sample will vary based on the assay format, the detection method and the nature of the cells or extracts used as the sample.
- source organism refers to the original organism from which the amino acid sequence of the subunit is derived, regardless of the organism the subunit is expressed in and ultimately isolated from.
- the DNA polymerase of the invention can be modified such that the polymerase lacks the 3'-5' exonuclease activity.
- a comparison of the amino acid sequence with other known DNA polymerases such as DNA polymerase I (Science 240:199-201 (1988)), ⁇ 29 (Cell 59:219-228 (1989)) and T5 DNA polymerase (U.S. Pat. No. 5,270,179) revealed potential amino acids implicated to be associated with 3'-5' activity. These amino acids are Asp(D) at amino acid 141 and Glu(E) at amino acid 143.
- the region of the polymerase which contains the exonuclease activity may also be identified by site specific mutation, random mutation or deletion.
- Mutation of the polymerase can be achieved as described above.
- a DNA fragment encoding the polymerase is mutated.
- the fragment is then expressed and the cells expressing the polymerase are assayed for polymerase and exonuclease activity.
- DNA polymerases described above which lack the 3'-5' exonuclease activity may be used in well known DNA sequencing, DNA labeling, and DNA amplification reactions.
- sequencing reactions (dideoxy DNA sequencing and cycle DNA sequencing of plasmid DNA) require the use of DNA polymerases.
- Dideoxy-mediated sequencing involves the use of a chain-termination technique which uses a specific polymer for extension by DNA polymerase, a base-specific chain terminator and the use of polyacrylamide gels to separate the newly synthesized chain-terminated DNA molecules by size so that at least a part of the nucleotide sequence of the original DNA molecule can be determined.
- a DNA molecule is sequenced by using four separate DNA sequence reactions, each of which contains different base-specific terminators.
- the first reaction will contain a G-specific terminator
- the second reaction will contain a T-specific terminator
- the third reaction will contain an A-specific terminator
- a fourth reaction may contain a C-specific terminator.
- Preferred terminator nucleotides include dideoxyribonucleoside triphosphates (ddNTPs) such as ddATT, ddTPP, ddGPP, and ddCPP. Analogs of dideoxyribonucleoside triphosphates may also be used and are well known in the art.
- ddNTPs When sequencing a DNA molecule, ddNTPs lack a hydroxyl residue at the 3' position of the deoxyribose base and thus, although they can be incorporated by DNA polymerases into the growing DNA chain, the absence of the 3'-hydroxy residue prevents formation of a phosphodiester bond resulting in termination of extension of the DNA molecule. Thus, when a small amount of one ddNTP is included in a sequencing reaction mixture, there is competition between extension of the chain and base-specific termination resulting in a population of synthesized DNA molecules which are shorter in length than the DNA template to be sequenced.
- populations of the synthesized DNA molecules can be separated by size so that at least a part of the nucleotide sequence of the original DNA molecule can be determined.
- DNA sequencing by dideoxy-nucleotides is well known and is described by Sambrook et al., In: Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989). As will be readily recognized, the DNA polymerase of the present invention may be used in such sequencing reaction.
- detectably labeled nucleotides are typically included in sequencing reactions. Any number of labeled nucleotides can be used in sequencing (or labeling) reactions, including, but not limited to, radioactive isotopes, fluorescent labels, chemiluminescent labels, bioluminescent labels, and enzyme labels.
- the DNA polymerases which lack the 3'-5' exonuclease activity may be particularly useful for incorporating ⁇ S nucleotides (dATP ⁇ S, dTTP ⁇ S, dCTP ⁇ S and dGTP ⁇ S) during sequencing (or labeling) reactions.
- PCR Polymerase chain reaction
- DNA polymerase and deoxyribonucleoside triphosphates are used to amplify a target DNA template.
- two primers one complementary to the 3' termini (or near the 3' termini) of the first strand of the DNA molecule to be amplified, and a second primer complementary to the 3' termini (or near the 3' termini) of the second strand of the DNA molecule to be amplified, are hybridized to their respective DNA molecules.
- DNA polymerase in the presence of deoxyribonucleoside triphosphates, allows the synthesis of a third DNA molecule complementary to the first strand and a fourth DNA molecule complementary to the second strand of the DNA molecule to be amplified. This synthesis results in two double stranded DNA molecules.
- double stranded DNA molecules may then be used as DNA templates for synthesis of additional DNA molecules by providing a DNA polymerase, primers, and deoxyribonucleoside triphosphates.
- the additional synthesis is carried out by "cycling" the original reaction (with excess primers and deoxyribonucleoside triphosphates) allowing multiple denaturing and synthesis steps.
- denaturing of double stranded DNA molecules to form single stranded DNA templates is accomplished by high temperatures.
- DNA polymerases which lack the 3'-5' exonuclease activity are ideally suited for PCR reactions, particularly where high temperatures are used to denature the DNA molecules during amplification.
- kits comprising certain DNA polymerases may be used for detectably labeling DNA molecules, DNA sequencing, or amplifying DNA molecules by well known techniques, depending on the content of the kit.
- kits may comprise a carrying means being compartmentalized to receive in close confinement therein one or more container means such as vials, test tubes and the like.
- container means such as vials, test tubes and the like.
- Each of such container means comprises components or a mixture of components needed to perform DNA sequencing, DNA labeling, or DNA amplification.
- a kit for sequencing DNA may comprise a number of container means.
- a first container means may, for example, comprise a substantially purified sample of the DNA polymerase having the molecular weight of about 95 kilodaltons.
- a second container means may comprise one or a number of types of nucleotides needed to synthesize a DNA molecule complementary to DNA template.
- a third container means may comprise one or a number different types of dideoxynucleoside triphosphates.
- additional container means may be included in the kit which comprise one or a number of DNA primers.
- a kit used for amplifying DNA will comprise, for example, a first container means comprising the substantially pure DNA polymerase and one or a number of additional container means which comprise a single type of nucleotide or mixtures of nucleotides.
- Various primers may or may not be included in a kit for amplifying DNA.
- the kit of the present invention may also include container means which comprise detectably labeled nucleotides which may be used during the synthesis or sequencing of a DNA molecule.
- labeled nucleotides may be used during the synthesis or sequencing of a DNA molecule.
- label include, but are not limited to, radioactive isotopes, fluorescent labels, chemiluminescent labels, bioluminescent labels and enzyme labels.
- the present invention relates to a nucleic acid probe for the detection of the presence of the above-described DNA polymerase in a sample comprising the above-described nucleic acid molecules or at least 20 contiguous nucleotides thereof (preferably at least 25, 30, 35, 40, or 50 thereof).
- the nucleic acid probe has the nucleic acid sequence set forth in SEQ ID NO:1 or at least 20 contiguous nucleotides thereof (preferably at least 25, 30, 35, 40, or 50 thereof).
- the nucleic acid probe encodes the amino acid sequence set forth in SEQ ID NO:2 or at least 39 contiguous amino acids thereof.
- the present invention provides for nucleic acid probes comprising a nucleic acid molecule which is capable of hybridizing to the DNA polymerase nucleic acid (preferably, the sequence of the nucleic acid is substantially the same as that depicted in SEQ ID NO: 1 or portions thereof of that are at least 20 nucleotides).
- the nucleic acid probe may be used to probe an appropriate chromosomal or cDNA library by usual hybridization methods to obtain another nucleic acid molecule of the present invention.
- a chromosomal DNA or cDNA library may be prepared from appropriate cells according to recognized methods in the art (cf. Molecular Cloning: A Laboratory Manual, second edition, edited by Sambrook, Fritsch, & Maniatis, Cold Spring Harbor Laboratory, 1989).
- nucleic acid primers having nucleotide sequences which correspond to N-terminal portion and the complement of C-terminal portion of the amino acid sequence of the polypeptide of interest.
- the synthesized nucleic acid probes may be used as primers in a polymerase chain reaction (PCR) carried out in accordance with recognized PCR techniques, essentially according to PCR Protocols, A Guide to Methods and Applications, edited by Michael et al., Academic Press, 1990, utilizing the appropriate chromosomal or cDNA library to obtain the fragment of the present invention.
- PCR polymerase chain reaction
- hybridization probes of the present invention can be labeled by standard labeling techniques such as with a radiolabel, enzyme label, fluorescent label, biotin-avidin label, chemiluminescence, and the like. After hybridization, the probes may be visualized using known methods.
- the nucleic acid probes of the present invention include RNA, as well as DNA probes, such probes being generated using techniques known in the art.
- a nucleic acid probe is immobilized on a solid support.
- solid supports include, but are not limited to, plastics such as polycarbonate, complex carbohydrates such as agarose and sepharose, and acrylic resins, such as polyacrylamide and latex beads. Techniques for coupling nucleic acid probes to such solid supports are well known in the art.
- test samples suitable for nucleic acid probing methods of the present invention include, for example, cells or nucleic acid extracts of cells, or biological fluids.
- the sample used in the above-described methods will vary based on the assay format, the detection method and the nature of the tissues, cells or extracts to be assayed. Methods for preparing nucleie acid extracts of cells are well known in the art and can be readily adapted in order to obtain a sample which is compatible with the method utilized.
- the present invention relates to a method of detecting the presence of the DNA polymerase nucleic acid in a sample comprising a) contacting the sample with the above-described nucleic acid probe, under conditions such that hybridization occurs, and b) detecting the presence of the probe bound to the nucleic acid molecule.
- a method of detecting the presence of the DNA polymerase nucleic acid in a sample comprising a) contacting the sample with the above-described nucleic acid probe, under conditions such that hybridization occurs, and b) detecting the presence of the probe bound to the nucleic acid molecule.
- One skilled in the art would select the nucleic acid probe according to techniques known in the art as described above.
- the present invention relates to a recombinant DNA molecule comprising, 5' to 3', a promoter effective to initiate transcription in a host cell and the above-described nucleic acid molecules.
- the present invention relates to a recombinant DNA molecule comprising a vector and an above-described nucleic acid molecules.
- the present invention relates to a nucleic acid molecule comprising a transcriptional region functional in a cell, a sequence complimentary to an RNA sequence encoding an amino acid sequence corresponding to the above-described polypeptide, and a transcriptional termination region functional in the cell.
- the above-described molecules are isolated and/or purified DNA molecules.
- the present invention relates to a cell or organism that contains an above-described nucleic acid molecule.
- the peptide is purified from cells which have been altered to express the peptide.
- a cell is said to be "altered to express a desired peptide" when the cell, through genetic manipulation, is made to produce a protein which it normally does not produce or which the cell normally produces at low levels.
- One skilled in the art can readily adapt procedures for introducing and expressing either genomic, cDNA, or synthetic sequences into either eukaryotic or prokaryotie cells.
- a nucleic acid molecule such as DNA, is said to be "capable of expressing" a polypeptide if it contains nucleotide sequences which contain transcriptional and translational regulatory information and such sequences are “operably linked” to nucleotide sequences which encode the polypeptide.
- An operable linkage is a linkage in which the regulatory DNA sequences and the DNA sequence sought to be expressed are connected in such a way as to permit gene sequence expression.
- the precise nature of the regulatory regions needed for gene sequence expression may vary from organism to organism, but shall in general include a promoter region which, in prokaryotes, contains both the promoter (which directs the initiation of RNA transcription) as well as the DNA sequences which, when transcribed into RNA, will signal synthesis initiation. Such regions will normally include those 5'-non-coding sequences involved with initiation of transcription and translation, such as the TATA box, capping sequence, CAAT sequence, and the like.
- the non-coding region 3' to the sequence encoding a DNA polymerase gene may be obtained by the above-described methods. Where the transcriptional termination signals are not satisfactorily functional in the expression host cell, then a 3' region functional in the host cell may be substituted.
- Two DNA sequences are said to be operably linked if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region sequence to direct the transcription of a DNA polymerase gene sequence, or (3) interfere with the ability of the a DNA polymerase gene sequence to be transcribed by the promoter region sequence.
- a promoter region would be operably linked to a DNA sequence if the promoter were capable of effecting transcription of that DNA sequence.
- the present invention encompasses the expression of the DNA polymerase gene (or a functional derivative thereof) in either prokaryotic or eukaryotic cells.
- Prokaryotic hosts are, generally, the most efficient and convenient for the production of recombinant proteins and, therefore, are preferred for the expression of the DNA polymerase gene.
- Prokaryotes most frequently are represented by various strains of E. coli. However, other microbial strains may also be used, including other bacterial strains.
- plasmid vectors that contain replication sites and control sequences derived from a species compatible with the host may be used. Examples of suitable plasmid vectors may include pBR322, pUC118, pUC119 and the like; suitable phage or bacteriophage vectors may include ⁇ gt10, ⁇ gt11 and the like; and suitable virus vectors may include pMAM-neo, pKRC and the like.
- the selected vector of the present invention has the capacity to replicate in the selected host cell.
- a preferred host for cloning the DNA polymerase gene of the invention is a prokaryotic host.
- the most preferred prokaryotic host is E. coli.
- the DNA polymerase gene of the present invention may be cloned in other prokaryotic hosts including, but not limited to, Escherichia, Bacillus, Streptomyces, Pseudomonas, Salmonella, Serratia, and Proteus.
- Bacterial hosts of particular interest include E. coli DH10B, which may be obtained from Life Technologies, Inc., (Gaithersburg, Maryland).
- Such promoters may be either constitutive or, more preferably, regulatable (i.e., inducible or derepressible).
- constitutive promoters include the int promoter of bacteriophage ⁇ , the bla promoter of the ⁇ lactamase gene sequence of pBR322, and the CAT promoter of the chloramphenicol acetyl transferase gene sequence of pBR325, and the like.
- inducible prokaryotic promoters examples include the major right and left promoters of bacteriophage ⁇ (P L and P R ), the trp, recA, lacZ, lacI, and gal promoters of E. coli, the ⁇ -amylase (Ulmanen et al., J. Bacteriol. 162:176-182 (1985)) and the delta-28-specific promoters of B.
- subtilis (Gilman et al., Gene sequence 32:11-20 (1984)), the promoters of the bacteriophages of Bacillus (Gryczan, In: The Molecular Biology of the Bacilli, Academic Press, Inc., NY (1982)), and Streptomyces promoters (Ward et al., Mol. Gen. Genet. 203:468-478 (1986)).
- Prokaryotic promoters are reviewed by Glick (J. Ind. Microbiol. 1:277-282 (1987)); Cenatiempo (Biochimie 68:505-516 (1986)); and Gottesman (Ann. Rev. Genet. 18:415-442 (1984)).
- ribosome binding sites are disclosed, for example, by Gold et al. (Ann. Rev. Microbiol. 35:365-404 (1981)).
- control sequences are dependent on the type of host cell used to express the gene.
- “cell,” “cell line,” and “cell culture” may be used interchangeably and all such designations include progeny.
- progeny include the primary subject cell and cultures derived therefrom, without regard to the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. However, as defined, mutant progeny have the same functionality as that of the originally transformed cell.
- Host cells which may be used in the expression systems of the present invention are not strictly limited, provided that they are suitable for use in the expression of the DNA polymerase of interest. Suitable hosts may often include eukaryotic cells.
- Preferred eukaryotic hosts include, for example, yeast, fungi, insect cells, mammalian cells either in vivo, or in tissue culture.
- Mammalian cells which may be useful as hosts include HeLa cells, cells of fibroblast origin such as VERO or CHO-K1, or cells of lymphoid origin and their derivatives.
- plant cells are also available as hosts, and control sequences compatible with plant cells are available, such as the cauliflower mosaic virus 35S and 19S, and nopaline synthase promoter and polyadenylation signal sequences.
- Another preferred host is an insect cell, for example Drosophila larvae.
- insect cells for example Drosophila larvae.
- the Drosophila alcohol dehydrogenase promoter can be used. Rubin, Science 240:1453-1459 (1988).
- baculovirus vectors can be engineered to express large amounts of the DNA polymerase in insects cells (Jasny, Science 238:1653 (1987); Miller et al., In: Genetic Engineering (1986), Setlow, J. K., et al., eds., Plenum, Vol. 8, pp. 277-297).
- Different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (e.g., glycosylation, cleavage) of proteins.
- Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed.
- expression in a bacterial system can be used to produce an unglycosylated core protein product.
- Expression in yeast will produce a glycosylated product.
- Expression in mammalian cells can be used to ensure "native" glycosylation of the heterologous DNA polymerase protein.
- different vector/host expression systems may effect processing reactions such as proteolytic cleavages to different extents.
- Any of a series of yeast gene sequence expression systems can be utilized which incorporate promoter and termination elements from the actively expressed gene sequences coding for glycolytic enzymes are produced in large quantities when yeast are grown in mediums rich in glucose.
- Known glycolytic gene sequences can also provide very efficient transcriptional control signals.
- Yeast provides substantial advantages in that it can also carry out posttranslational peptide modifications.
- Yeast recognizes leader sequences on cloned mammalian gene sequence products and secretes peptides bearing leader sequences (i.e., pre-peptides).
- leader sequences on cloned mammalian gene sequence products and secretes peptides bearing leader sequences (i.e., pre-peptides).
- pre-peptides i.e., pre-peptides
- transcriptional and translational regulatory sequences may be employed, depending upon the nature of the host.
- the transcriptional and translational regulatory signals may be derived from viral sources, such as adenovirus, bovine papilloma virus, simian virus, or the like, where the regulatory signals are associated with a particular gene sequence which has a high level of expression.
- promoters from mammalian expression products such as actin, collagen, myosin, and the like, may be employed.
- Transcriptional initiation regulatory signals may be selected which allow for repression or activation, so that expression of the gene sequences can be modulated.
- regulatory signals which are temperature-sensitive so that by varying the temperature, expression can be repressed or initiated, or are subject to chemical (such as metabolite) regulation.
- eukaryotic promoters include, for example, the promoter of the mouse metallothionein I gene sequence (Hamer et al., J. Mol. Appl. Gen. 1:273-288 (1982)); the TK promoter of Herpes virus (McKnight, Cell 31:355-365 (1982)); the SV40 early promoter (Benoist et al., Nature (London) 290:304-310 (1981)); the yeast gal4 gene sequence promoter (Johnston et al., Proc. Natl. Acad. Sci. (USA) 79:6971-6975 (1982); Silver et al., Proc. Natl. Acad. Sci. (USA) 81:5951-5955 (1984)).
- a DNA polymerase nucleic acid molecule and an operably linked promoter may be introduced into a recipient prokaryotic or eukaryotic cell either as a non-replicating DNA (or RNA) molecule, which may either be a linear molecule or, more preferably, a closed covalent circular molecule. Since such molecules are incapable of autonomous replication, the expression of the gene may occur through the transient expression of the introduced sequence. Alternatively, permanent expression may occur through the integration of the introduced DNA sequence into the host chromosome.
- a vector is employed which is capable of integrating the desired gene sequences into the host cell chromosome.
- Cells which have stably integrated the introduced DNA into their chromosomes can be selected by also introducing one or more markers which allow for selection of host cells which contain the expression vector.
- the marker may provide for prototrophy to an auxotrophic host, biocide resistance, e.g., antibiotics, or heavy metals, such as copper, or the like.
- the selectable marker gene sequence can either be directly linked to the DNA gene sequences to be expressed, or introduced into the same cell by co-transfection. Additional elements may also be needed for optimal synthesis of single chain binding protein mRNA. These elements may include splice signals, as well as transcription promoters, enhancers, and termination signals.
- cDNA expression vectors incorporating such elements include those described by Okayama, Molec. Cell. Biol. 3:280 (1983).
- the introduced nucleic acid molecule will be incorporated into a plasmid or vital vector capable of autonomous replication in the recipient host.
- a plasmid or vital vector capable of autonomous replication in the recipient host.
- Any of a wide variety of vectors may be employed for this purpose. Factors of importance in selecting a particular plasmid or viral vector include: the ease with which recipient cells that contain the vector may be recognized and selected from those recipient cells which do not contain the vector; the number of copies of the vector which are desired in a particular host; and whether it is desirable to be able to "shuttle" the vector between host cells of different species.
- Preferred prokaryotic vectors include plasmids such as those capable of replication in E.
- plasmids are, for example, disclosed by Sambrook (cf. Molecular Cloning: A Laboratory Manual, second edition, edited by Sambrook, Fritsch, & Maniatis, Cold Spring Harbor Laboratory, 1989)).
- Bacillus plasmids include pC194, pC221, pT127, and the like. Such plasmids are disclosed by Gryczan (In: The Molecular Biology of the Bacilli, Academic Press, N.Y. (1982), pp. 307-329).
- Suitable Streptomyces plasmids include pIJ101 (Kendall et al., J.
- Preferred eukaryotic plasmids include, for example, BPV, vaccinia, SV40, 2-micron circle, and the like, or their derivatives.
- Such plasmids are well known in the art (Botstein et al., Miami Wntr. Symp. 19:265-274 (1982); Broach, In: The Molecular Biology of the Yeast Saccharomyces: Life Cycle and Inheritance, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., p. 445-470 (1981); Broach, Cell 28:203-204 (1982); Bollon et al., J. Clin. Hematol. Oncol. 10:39-48 (1980); Maniatis, In: Cell Biology: A Comprehensive Treatise, Vol. 3, Gene Sequence Expression, Academic Press, N.Y., pp. 563-608 (1980)).
- the DNA construct(s) may be introduced into an appropriate host cell by any of a variety of suitable means, i.e., transformation, transfection, conjugation, protoplast fusion, electroporation, particle gun technology, calcium phosphate-precipitation, direct microinjection, and the like.
- recipient cells are grown in a selective medium, which selects for the growth of vector-containing cells.
- Expression of the cloned gene molecule(s) results in the production of the DNA polymerase or fragments thereof. This can take place in the transformed cells as such, or following the induction of these cells to differentiate (for example, by administration of bromodeoxyuracil to neuroblastoma cells or the like).
- the polymerases of the present invention are preferably produced by fermentation of the recombinant host containing and expressing the cloned DNA polymerase gene.
- the DNA polymerase of the present invention may be isolated from any strain which produces the polymerase of the present invention.
- Any nutrient that can be assimilated by a host containing the native or cloned DNA polymerase gene may be added to the culture medium.
- Optimal culture conditions should be selected case by case according to the strain used and the composition of the culture medium.
- Antibiotics may also be added to the growth media to insure maintenance of vector DNA containing the desired gene to be expressed.
- Culture conditions for Desulfurococcus strain Tok12-S 1 have, for example, been described by Cowan et al., Biochem, J. 247:121-133 (1987). Media formulations are also described by Finegold et al., In: Diagnostic Microbiology (5th ed.), The C.V. Mosby Company, St. Louis, Mich. (1978) and Sambrook et al., In: Molecular Cloning, A Laboratory Manual (2nd ed.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).
- Native and recombinant host cells producing the DNA polymerase of this invention can be separated from liquid culture, for example, by centrifugation.
- the collected microbial cells are dispersed in a suitable buffer, and then broken down by ultrasonic treatment or by other well known procedures to allow extraction of the polymerases by the buffer solution.
- the DNA polymerase can be purified by standard protein purification techniques such as extraction, precipitation, chromatography, affinity chromatography, electrophoresis or the like.
- Assays to detect the presence of the DNA polymerase during purification are well known in the art and can be used during conventional biochemical purification methods to determine the presence of these enzymes.
- the present invention relates to an antibody having binding affinity to the DNA polymerase, or a binding fragment thereof.
- the polypeptide has the amino acid sequence set forth in SEQ ID NO:2, or mutant or species variation thereof, or at least 39 contiguous amino acids thereof (preferably, at least 40, 50, or 100 contiguous amino acids thereof).
- the present invention relates to an antibody having binding affinity to the DNA polymerase, or a binding fragment thereof.
- Those which bind selectively to the DNA polymerase would be chosen for use in methods which could include, but should not be limited to, the analysis of altered DNA polymerase expression in tissue containing the DNA polymerase.
- the DNA polymerase peptide of the present invention can be used to produce antibodies or hybridomas.
- One skilled in the art will recognize that if an antibody is desired, such a peptide would be generated as described herein and used as an immunogen.
- the antibodies of the present invention include monoclonal and polyclonal antibodies, as well fragments of these antibodies.
- Antibody fragments which contain the idiotype of the molecule can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab') 2 fragment; the Fab' fragments, and the Fab fragments.
- the present invention relates to a hybridoma which produces the above-described monoclonal antibody, or binding fragment thereof.
- a hybridoma is an immortalized cell line which is capable of secreting a specific monoclonal antibody.
- Any animal which is known to produce antibodies can be immunized with the selected polypeptide.
- Methods for immunization are well known in the art. Such methods include subcutaneous or interperitoneal injection of the polypeptide in a suitable vehicle.
- One skilled in the art will recognize that the amount of polypeptide used for immunization will vary based on the animal which is immunized, the antigenicity of the polypeptide and the site of injection.
- the polypeptide may be modified or administered in an adjuvant in order to increase the peptide antigenicity.
- Methods of increasing the antigenicity of a polypeptide are well known in the art. Such procedures include coupling the antigen with a heterologous protein (such as globulin or ⁇ -galactosidase) or through the inclusion of an adjuvant during immunization.
- a heterologous protein such as globulin or ⁇ -galactosidase
- spleen cells from the immunized animals are removed, fused with myeloma cells, and allowed to become monoclonal antibody producing hybridoma cells.
- any one of a number of methods well known in the art can be used to identify the hybridoma cell which produces an antibody with the desired characteristics. These include screening the hybridomas with an ELISA assay, western blot analysis, or radioimmunoassay (Lutz et al., Exp. Cell Res. 175:109-124 (1988)).
- Hybridomas secreting the desired antibodies are cloned and the class and subclass is determined using procedures known in the art (Campbell, Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology, supra (1984)).
- antibody containing antisera is isolated from the immunized animal and is screened for the presence of antibodies with the desired specificity using one of the above-described procedures.
- Antibodies are detectably labeled.
- Antibodies can be detectably labeled through the use of radioisotopes, affinity labels (such as biotin, avidin, and the like), enzymatic labels (such as horse radish peroxidase, alkaline phosphatase, and the like) fluorescent labels (such as FITC or rhodamine, and the like), paramagnetic atoms, and the like. Procedures for accomplishing such labeling are well-known in the art, for example, see (Sternberger et al., J. Histochem. Cytochem. 18:315 (1970); Bayer et al., Meth. Enzym.
- the labeled antibodies of the present invention can be used for in vitro, in vivo, and in situ assays to identify cells or tissues which express a specific peptide.
- the above-described antibodies are immobilized on a solid support.
- solid supports include plastics such as polycarbonate, complex carbohydrates such as agarose and sepharose, acrylic resins and such as polyacrylamide and latex beads. Techniques for coupling antibodies to such solid supports are well known in the art (Weir et al., "Handbook of Experimental Immunology” 4th Ed., Blackwell Scientific Publications, Oxford, England, Chapter 10 (1986); Jacoby et al., Meth. Enzym. 34 Academic Press, N.Y. (1974)).
- the immobilized antibodies of the present invention can be used for in vitro, in vivo, and in situ assays as well as in immunochromotography.
- the present invention relates to a method for purifying thermostable proteins. More specifically, the method for purifying thermostable proteins (preferably, proteins larger than 50 kd in size, more specifically, thermostable DNA polymerases) comprises heating a sample above 70° C. containing the thermostable protein and then, purifying the thermostable proteins by gel filtration.
- the method for purifying thermostable proteins comprises heating a sample above 70° C. containing the thermostable protein and then, purifying the thermostable proteins by gel filtration.
- the method is based on the unexpected discovery that heating an aqueous E. coli extract differentially precipitates large E. coli proteins having molecular weights similar to DNA polymerase. Therefore, the cloned DNA polymerase is predominantly contaminated with smaller E. coli proteins. After heating, the thermostable proteins are easily purified by methods well known in the art, for example, by using gel filtration columns.
- the DNA polymerase of the present invention is purified by heating E. coli extracts at 75° C. for 30 min. and then purifying the soluble proteins further with gel filtration.
- Desulfurococcus strain Tok12-S1 cell paste was obtained from PEL (Pacific Enzymes Limited, Aukland, New Zealand)(Patel et al., New Zealand J. Marine Freshwater Res. 20:439-445 (1986)).
- E. coli strain DH10B Life Technologies, Inc., Gaithersburg, Md.
- CJ374 Cathy Joyce, Yale University
- E. coli strains were grown in 2X LB broth base (Lennox L broth base: GIBCO/BRL) medium. Transformed cells were incubated in SOC (2% tryptone, 0.5 % yeast extract, 10 mM NaCl, 2.5M KC1, 20 mM KCl, 20 mM glucose, 10 mM MgCl 2 , and 10 mM MgSO 4 per liter) before plating.
- antibiotic supplements were 100 micrograms/ml ampicillin, 50 micrograms/ml kanamycin, 30 micrograms/ml chloramphenicol.
- Desulfurococcus chromosomal DNA was isolated from 1.1 g of cells suspended in 2.5 ml of TNE buffer (50 mM Tris-HCl, pH8.0, 50 mM NaCl, 10 mM EDTA) and treated with 1% SDS for 10 minutes at 37° C. DNA was extracted with phenol by gently rocking the lysed cells overnight at 4 ° C. The 2O aqueous layer was extracted with chloroform: isoamyl alcohol. The resulting chromosomal DNA was further purified by centrifugation in a CsCl density gradient. Chromosomal DNA isolated from the density gradient was extracted three times with 20X SSC saturated isopropanol and dialyzed overnight against a buffer containing 10 mM Tris-HCl, pH 8.0 and 1 mM EDTA.
- PCR Polymerase Chain Reaction
- the Polymerase Chain Reaction is a powerful technique for amplifying regions from small quantities of DNA. Specific deoxyoligonucleotides can be utilized in this reaction to obtain DNA sizes of predicted length.
- the known amino acid sequences of DNA polymerases contain many conserved homologous regions. Degenerate deoxyoligonucleotides were designed to anneal in 2 of these regions of conserved homology to generate a specific PCR product of about 600 bp.
- the PCR product may be sequenced to confirm that it was generated from DNA polymerase sequences.
- the same PCR product may also be used as a probe to hybridize to the Desulfurococcus chromosomal DNA in order to obtain the remainder of the polymerase gene.
- the forward primer (1906) 26 nucleotides and the reverse primer (1910) 31 nucleotides are listed below:
- Both primers were designed to contain restriction sites near the 5' end for use in cloning the PCR product into a vector.
- the forward primer contains an XbaI site while the reverse primer contains a BamHI site.
- the 5' nine nucleotides of the forward primer and the 5' eight nucleotides of the reverse primer have no homology to the polymerase.
- the conditions used were as follows: 50ng of Desulfurococcus chromosomal DNA and 1 micromoles of forward and reverse primers were added to a PCR reaction and incubated using the following conditions: 1 cycle of 94° C.
- Taq DNA polymerase Perkin-Elmer, Cetus
- 25 cycles were performed as follows: denaturation at 94° C., 30 seconds; primer annealing at 50° C., 30 seconds; and extension at 72° C., 2 minutes.
- the PCR reaction was purified by adding 1/10 volume 3M ammonium acetate and 2.5 volumes 95 % ethanol.
- the DNA was collected in 30 microliter of REact 2 (LTI) containing 15 units of XbaI and BamHI. The sample was incubated for 45 minutes at 37° C. and applied to an agarose gel.
- LTI REact 2
- the 600 bp fragment was extracted from the gel and purified away from the agarose using a GeneClean KitTM (BIO-101, La Jolla, Calif.).
- a 10 microliter ligation reaction containing the purified PCR product, the vector pUC19 digested with XbaI and BamHI (purified as above), 1X ligase buffer (LTI), and 1 unit of T4 DNA ligase (LTI) was incubated for 1.5 hours at 22° C.
- Competent DH10B cells were transformed with 0.3 microliters of the ligation reaction mix. Transformants were selected on agar plates containing ampicillin incubated at 30° C.
- Plasmid DNA from four colonies was isolated and screened by miniprep DNA analysis to determine if the clones contained the 600bp PCR product. Three of the four clones contained the desired insert. One of the clones was further analyzed by DNA sequence analysis and determined to contain a specific region of a DNA polymerase gene based upon the nucleic and amino acid homology to other known DNA polymerases.
- the chromosomal DNA isolated in Example 2 was used to construct a genomic library in the cosmid pCP13. Briefly, 100 micrograms of Desulfurococcus chromosomal DNA was partially digested with Sau3AI for 1 hour at 37° C. and then concentrated by EtOH precipitation. The partially digested chromosomal DNA was ligated into the cosmid pCP13 digested with BamHI and dephosphorylated with calf intestinal phosphatase. Ligation of the partially digested Desulfurococcus DNA and the BamHI cleaved pCP13 DNA was carried out with 1 unit of T4 DNA ligase at 22° C. for 18 hours.
- ligation reaction After ligation, a portion of the ligation reaction was packaged into lambda phage particles (Lambda Packaging Kit obtained from Life Technologies, Inc., Gaithersburg, Md.) and used to infect DH10B cells. Infected cells were applied onto tetracycline containing plates. Approximately 3,000 tetracycline resistant colonies were obtained. Serial dilutions were made such that approximately 200 to 300 tetracycline resistant colonies were applied per plate.
- the filters were air dried and baked in a vacuum oven for 1 hour at 80° C.
- the filters were then probed with a 32P random primer labelled 600 bp Desulfurococcus polymerase gene fragment described in Example 3.
- the DNA from colonies eliciting a signal were isolated and characterized by Southern Blot analysis and comparing DNA sequence to other known DNA polymerases. Analysis of the sequence homology data revealed the presence of two intervening sequences in the Desulfurococcus DNA polymerase gene. The intervening sequences were removed and the resulting Desulfurococcus DNA polymerase gene was cloned into an expression vector. Briefly, an NdeI site was created by PCR to include the initiation codon of the polymerase gene within the NdeI site.
- Restriction sites were also generated at the intervening sequence junctions by PCR. These restriction sites were designed to contain compatible ends such that when the pieces were joined together it would generate an in-frame Desulfurococcus DNA polymerase gene without intervening sequences.
- the intact gene was then cloned in pRE1, under control of the pL promoter.
- the resulting plasmid was used to transform competent CJ374. The transformants were selected on ampicillin and chloramphenicol plates. The colonies were screened by plasmid DNA restriction analysis and the positive clones were then assayed for heat-stable polymerase activity.
- the DNA from three separate PCR reactions were ligated to each other such that the intervening sequences were eliminated from the resulting clone.
- the two oligos designed for first PCR reaction are as follows:
- the forward primer creates a NdeI site at the initiation codon of the polymerase gene, while the reverse primer includes a MscI site 7 base pairs away from the junction of the polymerase gene and the first intervening sequence.
- the strategy was to ligate the second PCR product to the first PCR product at the MscI site.
- the PCR reactions were carried out as described in Example 3 with the following exceptions: (1) where 25 cycles were use in Example 3, only 8 cycles were used to minimize the possibility of a misincorporated base pair, or (2) a portion of the PCR product was treated with uracil-D-glycosylase (LTI) and cloned into pAMP1 (LTI) to generate pBJS96.
- the 2 remaining PCR products were treated in a similar manner.
- the three separate PCR products were ligated together at the appropriate restriction sites to generate pBJS107.
- the remaining portion of the carboxyl terminus was cloned into the EcoRI site on a 1.5Kb fragment resulting in (pBJS103).
- the resulting construction contained the entire polymerase gene without the intervening sequences and was cloned into the expression vector pRE1 resulting in (pBJS108).
- DNA sequence was obtained from subclones of the cosmid clone DTOK/pCP13. The position of the methionine start codon and the intron/exon junctions were determined based on amino acid homology to other polymerases. PCR was then performed on the polymerase gene subclones to incorporate an NdeI site at the start methionine residue and other blunt end restriction sites at the intron/exon junctions. The PCR products were first cloned separately into pAMP1 (LTI) and then pieced together at the created restriction sites. The restriction sites introduced were site-specific changes in 25 the DNA in order to create the recognition sites but did not alter the amino acid sequence. The carboxyl end of the gene was cloned on an EcoRI fragment.
- pREI is an E. coli plasmid which contains the pL promoter from the E. coli bacteriophage lambda. Expression from the pL promoter can be regulated by the temperature sensitive mutant repressor cI857.
- Competent cells containing a plasmid carrying the cI857 repressor gene (CJ374, Cathy Joyce, Yale University) were transformed with the DTOK polymerase gene in the pREI vector.
- E. coli CJ374 containing pBJS108 was named E. coli BJS108.
- Alteration of the Asp141 and Glu143 to Ala141 and Ala143 has resulted in 10,000 fold lower level of 3'-5' exonuclease activity.
- the oligo used for the mutation was 5' GAC GAG GAG CTC AGG ATG CTC GCC TTC GCG ATC GCG ACG CTC TAC CAT 3' (SEQ ID NO: 11).
- the mutagenesis was done by PCR. However, one can utilize another well known technique called Kunkel mutagenesis (Kunkel, Proc. Natl. Acad. Sci. 82:488-492 (1985)) to obtain the same result.
- Kunkel mutagenesis Kunkel, Proc. Natl. Acad. Sci. 82:488-492 (1985)
- the supernatant fraction was collected (FRI 3.5 ml) and applied to a previously equilibrated 1 ml HiTrap Blue column (Pharmacia). The column was washed until baseline OD 280 was achieved. Elution was effected with a linear 30 column volume gradient of buffer A (50 mM Tris, pH 7.5, 1.0 mM EDTA, 10% glycerol, 0.05 % Tween-20, 0.05 % NP-40, and 5.0 mM DTT or 1.0 mM ⁇ ME) to buffer A and 2 M KC1. 500 ⁇ l fractions were collected. Polymerase activity eluted as a single peak centered in fraction 46.
- buffer A 50 mM Tris, pH 7.5, 1.0 mM EDTA, 10% glycerol, 0.05 % Tween-20, 0.05 % NP-40, and 5.0 mM DTT or 1.0 mM ⁇ ME
- the Desulfurococcus polymerase was purified 41-fold in 67 % yield to a specific activity of 409 u/mg. Fractions containing greater than 50% peak activity were pooled and concentrated with a Centricon-30 (Amicon).
- E. coli cells expressing cloned Desulfurococcus DNA polymerase were lysed by sonication (3 thirty-second bursts with a microtip at the maximum setting with a Heat Systems Ultrasonics Inc., model 375 sonicator) in 20 ml of ice cold extraction buffer (50 mM Tris HCl, pH 7.5, 8% glycerol, 3 mM mercaptoethanol, 10 mM KCl, 1 mM EDTA, 0.5 mM PMSF, and 0.05% each of Tween-20 and NP-40). This was centrifuged at 17,000xg at 4° C. for 60 min. and the supernatant was heated to 75° C. for 30 min.
- sonication thirty-second bursts with a microtip at the maximum setting with a Heat Systems Ultrasonics Inc., model 375 sonicator
- Fractions containing polymerase activity were pooled, concentrated with a Centriprep 10 (Amicon Inc.), loaded on a 25 ml Superdex 75 FPLC column (Pharmacia), and eluted with buffer A containing 150 mM KCl.
- the molecular weight of 95 kilodaltons was determined by electrophoresis in a 7.5 % polyacrylamide, SDS gel by the method of Laemmli, U.K., Nature (Lond.) 227:680-685 (1970). A single protein band was detected by silver staining (Bio-Rad).
- the Desulfurococcus DNA polymerase incorporated 35 S!dATP ⁇ S relative to dATP at a frequency at least 7 times greater than for Taq DNA polymerase.
Abstract
Description
TABLE 1 ______________________________________ Original Residue Exemplary Substitutions ______________________________________ Ala gly; ser Arg lys Asn gln; his Asp glu Cys ser Gln asn Glu asp Gly ala; pro His asn; gln Ile leu; val Leu ile; val Lys arg; gln; glu Met leu; tyr; ile Phe met; leu; tyr Ser thr Thr ser Trp tyr Tyr trp; phe Val ile; leu ______________________________________
______________________________________ Primer # Site ______________________________________ 2258 NdeI 2348 MscI 2349 MscI 2296 EcoRV 2297 ScaI 2264 EcoRI ______________________________________
__________________________________________________________________________ SEQUENCE LISTING (1) GENERAL INFORMATION: (iii) NUMBER OF SEQUENCES: 11 (2) INFORMATION FOR SEQ ID NO:1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1193 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 6..1193 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: GAGTTATGATCCTCGATGCTGACTACATCACCGAAGACGGAAAGCCC47 MetIleLeuAspAlaAspTyrIleThrGluAspGlyLysPro 1510 GTCATAAGGGTCTTCAAGAAGGAGAAGGGCGAGTTTAAGATAGACTAC95 ValIleArgValPheLysLysGluLysGlyGluPheLysIleAspTyr 15202530 GACAGGACTTTCGAGCCCTACATCTACGCCCTCCTGAAGGACGATTCC143 AspArgThrPheGluProTyrIleTyrAlaLeuLeuLysAspAspSer 354045 GCCATTGAGGACATCAAGAAGATCACCGCCGAGAGGCACGGCACCACC191 AlaIleGluAspIleLysLysIleThrAlaGluArgHisGlyThrThr 505560 GTTAGAGTTACCCGGGCGGAGAGGGTGAAGAAGAAGTTCCTCGGCAGG239 ValArgValThrArgAlaGluArgValLysLysLysPheLeuGlyArg 657075 CCGGTGGAGGTCTGGAAGCTCTACTTCACCCACCCCCAGGACGTTCCC287 ProValGluValTrpLysLeuTyrPheThrHisProGlnAspValPro 808590 GCGATCAGGGACAAGATCAGGGAGCATCCGGCGGTTGTTGACATCTAC335 AlaIleArgAspLysIleArgGluHisProAlaValValAspIleTyr 95100105110 GAGTACGACATACCCTTCGCGAAGCGCTACCTCATAGACAGGGGCTTA383 GluTyrAspIleProPheAlaLysArgTyrLeuIleAspArgGlyLeu 115120125 ATCCCTATGGAGGGGGACGAGGAGCTCAGGATGCTCGCCTTCGACATC431 IleProMetGluGlyAspGluGluLeuArgMetLeuAlaPheAspIle 130135140 GAGACGCTCTACCATGATGGGGAGGAGTTTGGCGAGGGGCCTATCCTG479 GluThrLeuTyrHisAspGlyGluGluPheGlyGluGlyProIleLeu 145150155 ATGATAACGTACGCCGATGAAGAGGGAGCGCGCGTTATCACCTGGAAG527 MetIleThrTyrAlaAspGluGluGlyAlaArgValIleThrTrpLys 160165170 AATATCGACCTCCCCTACGTGGAGAGCGTTTCCACCGAGAGAGAGATG575 AsnIleAspLeuProTyrValGluSerValSerThrGluArgGluMet 175180185190 ATAAAGCGCTCCCTCAAGGTAATCCAGGAGAAGGATCCCGATGTGCTC623 IleLysArgSerLeuLysValIleGlnGluLysAspProAspValLeu 195200205 ATAACCTACAACGGCGACAACTTCGACTTTGCCTACCTCAAGAAGCGC671 IleThrTyrAsnGlyAspAsnPheAspPheAlaTyrLeuLysLysArg 210215220 TCAGAAATGCTCGGCGTCAAGTTTATCCTCGGAAGGGACGGGAGCGAA719 SerGluMetLeuGlyValLysPheIleLeuGlyArgAspGlySerGlu 225230235 CCAAAAATTCAGCGCATGGGAGACCGCTTTGCGGAGGTGAAGGGGAGA767 ProLysIleGlnArgMetGlyAspArgPheAlaGluValLysGlyArg 240245250 ATACACTTCGACCTCTACCCGGTTATAAGGAGGACGATTAACCTTCCC815 IleHisPheAspLeuTyrProValIleArgArgThrIleAsnLeuPro 255260265270 ACCTACACCCTCGAGACAGTCTACGAGCCGGTTTTTGGGCAACCAAAG863 ThrTyrThrLeuGluThrValTyrGluProValPheGlyGlnProLys 275280285 GAGAAGGTCTACGCGGAAGAGATAGCGCGGGCCTGGGAGAGCGGGGAA911 GluLysValTyrAlaGluGluIleAlaArgAlaTrpGluSerGlyGlu 290295300 GGCTTGGAAAGGGTGGCCCGCTATTCCATGGAGGACGCAAAGGCAACT959 GlyLeuGluArgValAlaArgTyrSerMetGluAspAlaLysAlaThr 305310315 TACGAACTCGGCAAAGAGTTCTTCCCGATGGAGGCCCAGCTCTCGCGC1007 TyrGluLeuGlyLysGluPhePheProMetGluAlaGlnLeuSerArg 320325330 CTCGTGGGCCAGAGCCTCTGGGATGTATCGCGCTCGAGCACAGGAAAC1055 LeuValGlyGlnSerLeuTrpAspValSerArgSerSerThrGlyAsn 335340345350 TTAGTTGAGTGGTTTCTCCTGAGGAAGGCCTACGAGAGGAACGACGTC1103 LeuValGluTrpPheLeuLeuArgLysAlaTyrGluArgAsnAspVal 355360365 GCGCCAAACAAGCCTGACGAGGAGGAGTTAGCAAGGAGAGCGGAGACG1151 AlaProAsnLysProAspGluGluGluLeuAlaArgArgAlaGluThr 370375380 TACGCGGGTGGATATGTCAAAGAGCCAGAAAAAGGTTTGTGG1193 TyrAlaGlyGlyTyrValLysGluProGluLysGlyLeuTrp 385390395 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 396 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: MetIleLeuAspAlaAspTyrIleThrGluAspGlyLysProValIle 151015 ArgValPheLysLysGluLysGlyGluPheLysIleAspTyrAspArg 202530 ThrPheGluProTyrIleTyrAlaLeuLeuLysAspAspSerAlaIle 354045 GluAspIleLysLysIleThrAlaGluArgHisGlyThrThrValArg 505560 ValThrArgAlaGluArgValLysLysLysPheLeuGlyArgProVal 65707580 GluValTrpLysLeuTyrPheThrHisProGlnAspValProAlaIle 859095 ArgAspLysIleArgGluHisProAlaValValAspIleTyrGluTyr 100105110 AspIleProPheAlaLysArgTyrLeuIleAspArgGlyLeuIlePro 115120125 MetGluGlyAspGluGluLeuArgMetLeuAlaPheAspIleGluThr 130135140 LeuTyrHisAspGlyGluGluPheGlyGluGlyProIleLeuMetIle 145150155160 ThrTyrAlaAspGluGluGlyAlaArgValIleThrTrpLysAsnIle 165170175 AspLeuProTyrValGluSerValSerThrGluArgGluMetIleLys 180185190 ArgSerLeuLysValIleGlnGluLysAspProAspValLeuIleThr 195200205 TyrAsnGlyAspAsnPheAspPheAlaTyrLeuLysLysArgSerGlu 210215220 MetLeuGlyValLysPheIleLeuGlyArgAspGlySerGluProLys 225230235240 IleGlnArgMetGlyAspArgPheAlaGluValLysGlyArgIleHis 245250255 PheAspLeuTyrProValIleArgArgThrIleAsnLeuProThrTyr 260265270 ThrLeuGluThrValTyrGluProValPheGlyGlnProLysGluLys 275280285 ValTyrAlaGluGluIleAlaArgAlaTrpGluSerGlyGluGlyLeu 290295300 GluArgValAlaArgTyrSerMetGluAspAlaLysAlaThrTyrGlu 305310315320 LeuGlyLysGluPhePheProMetGluAlaGlnLeuSerArgLeuVal 325330335 GlyGlnSerLeuTrpAspValSerArgSerSerThrGlyAsnLeuVal 340345350 GluTrpPheLeuLeuArgLysAlaTyrGluArgAsnAspValAlaPro 355360365 AsnLysProAspGluGluGluLeuAlaArgArgAlaGluThrTyrAla 370375380 GlyGlyTyrValLysGluProGluLysGlyLeuTrp 385390395 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: CGATCTCTAGARAGAGARATGATAAAG27 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: CGATCGGATCCCACAAMCCYTTTTCTGGCTC31 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: CUACUACUACUATAACATATGATCCTCGATGCTGAC36 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 34 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: CAUCAUCAUCAUGACTGTTGCCCAAGATCTTGAT34 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 48 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: CUACUACUACAUTTGGCCAACAGTTATTACGGCTACTACGCGTACGCA48 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: CAUCAUCAUCAUATCGATATCCGCGTAAAGCACTTT36 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 38 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: CUACUACUACUAACTAGTACTGACGGTTTCTTTGCCAC38 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: CAUCAUCAUCAUTGAGAATTCTTTAGCCTTATTTTT36 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 48 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: GACGAGGAGCTCAGGATGCTCGCCTTCGCGATCGCGACGCTCTACCAT48
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/229,284 USH1531H (en) | 1994-04-18 | 1994-04-18 | Thermophilic DNA polymerase |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/229,284 USH1531H (en) | 1994-04-18 | 1994-04-18 | Thermophilic DNA polymerase |
Publications (1)
Publication Number | Publication Date |
---|---|
USH1531H true USH1531H (en) | 1996-05-07 |
Family
ID=22860551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/229,284 Abandoned USH1531H (en) | 1994-04-18 | 1994-04-18 | Thermophilic DNA polymerase |
Country Status (1)
Country | Link |
---|---|
US (1) | USH1531H (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997009451A1 (en) * | 1995-09-08 | 1997-03-13 | Life Technologies, Inc. | Cloned dna polymerases from thermotoga and mutants thereof |
US5756334A (en) * | 1990-04-26 | 1998-05-26 | New England Biolabs, Inc. | Thermostable DNA polymerase from 9°N-7 and methods for producing the same |
WO1999007837A1 (en) * | 1997-08-06 | 1999-02-18 | Diversa, Inc. | Isolation and identification of novel polymerases |
US5912155A (en) * | 1994-09-30 | 1999-06-15 | Life Technologies, Inc. | Cloned DNA polymerases from Thermotoga neapolitana |
WO1999064438A1 (en) * | 1998-06-11 | 1999-12-16 | Clontech Laboratories, Inc. | Thermostable polymerase |
US6015668A (en) * | 1994-09-30 | 2000-01-18 | Life Technologies, Inc. | Cloned DNA polymerases from thermotoga and mutants thereof |
US6407144B1 (en) | 2000-04-04 | 2002-06-18 | Westinghouse Savannah River Company, Llc | Combination biological and microwave treatments of used rubber products |
US6420457B1 (en) | 2000-04-04 | 2002-07-16 | Westinghouse Savannah River Company, Llc | Microwave treatment of vulcanized rubber |
US6479558B1 (en) | 2000-04-04 | 2002-11-12 | Westinghouse Savannah River Company | Microbial processing of used rubber |
US20030003490A1 (en) * | 2000-02-07 | 2003-01-02 | Illumina, Inc. | Nucleic acid detection methods using universal priming |
US20030143618A1 (en) * | 2002-01-23 | 2003-07-31 | Yves Hatzfield | Method for easy cloning and selection of chimeric DNA molecules |
US20030170684A1 (en) * | 2000-02-07 | 2003-09-11 | Jian-Bing Fan | Multiplexed methylation detection methods |
US20040259105A1 (en) * | 2002-10-03 | 2004-12-23 | Jian-Bing Fan | Multiplex nucleic acid analysis using archived or fixed samples |
US7049101B1 (en) | 1997-08-06 | 2006-05-23 | Diversa Corporation | Enzymes having high temperature polymerase activity and methods of use thereof |
US7056703B2 (en) | 1997-08-06 | 2006-06-06 | Diversa Corporation | Polypeptides having polymerase activity and methods of use thereof |
US7582420B2 (en) | 2001-07-12 | 2009-09-01 | Illumina, Inc. | Multiplex nucleic acid reactions |
US7955794B2 (en) | 2000-09-21 | 2011-06-07 | Illumina, Inc. | Multiplex nucleic acid reactions |
US8076063B2 (en) | 2000-02-07 | 2011-12-13 | Illumina, Inc. | Multiplexed methylation detection methods |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4795699A (en) * | 1987-01-14 | 1989-01-03 | President And Fellows Of Harvard College | T7 DNA polymerase |
US4889818A (en) * | 1986-08-22 | 1989-12-26 | Cetus Corporation | Purified thermostable enzyme |
US5047342A (en) * | 1989-08-10 | 1991-09-10 | Life Technologies, Inc. | Cloning and expression of T5 DNA polymerase |
EP0455430A2 (en) * | 1990-04-26 | 1991-11-06 | New England Biolabs, Inc. | Purified thermostable DNA polymerase obtainable from Thermococcus litoralis |
EP0547920A2 (en) * | 1991-12-18 | 1993-06-23 | New England Biolabs, Inc. | Recombinant thermostable DNA polymerase from archaebacteria |
-
1994
- 1994-04-18 US US08/229,284 patent/USH1531H/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4889818A (en) * | 1986-08-22 | 1989-12-26 | Cetus Corporation | Purified thermostable enzyme |
US4795699A (en) * | 1987-01-14 | 1989-01-03 | President And Fellows Of Harvard College | T7 DNA polymerase |
US5047342A (en) * | 1989-08-10 | 1991-09-10 | Life Technologies, Inc. | Cloning and expression of T5 DNA polymerase |
EP0455430A2 (en) * | 1990-04-26 | 1991-11-06 | New England Biolabs, Inc. | Purified thermostable DNA polymerase obtainable from Thermococcus litoralis |
EP0547920A2 (en) * | 1991-12-18 | 1993-06-23 | New England Biolabs, Inc. | Recombinant thermostable DNA polymerase from archaebacteria |
Non-Patent Citations (40)
Title |
---|
Bergquist et al., "Genetics and Potential Biotechnological Applications of Thermophilic and Extremely Thermophilic Micro-organisms," Biotech. & Genet. Eng. Rev. 5:199-244 (Sep. 1987). |
Bergquist et al., Genetics and Potential Biotechnological Applications of Thermophilic and Extremely Thermophilic Micro organisms, Biotech. & Genet. Eng. Rev. 5:199 244 (Sep. 1987). * |
Blanco et al., "Evidence favouring the hypothesis of a conserved 3'-5' exonuclease active site in DNA-dependent DNA polymerases," Gene 112:139-144 (1992). |
Blanco et al., Evidence favouring the hypothesis of a conserved 3 5 exonuclease active site in DNA dependent DNA polymerases, Gene 112:139 144 (1992). * |
Bragger et al., "Very stable enzymes from extremely thermophilic archaebacteria and eubacteria," Appl. Microbiol. Biotechnol. 31:556-561 (1989). |
Bragger et al., Very stable enzymes from extremely thermophilic archaebacteria and eubacteria, Appl. Microbiol. Biotechnol. 31:556 561 (1989). * |
Braithwaite & Ito, "Compilation, alignment, and phylogenetic relationships of DNA polymerases," Nucl. Acids Res. 21:787-802 (1993). |
Braithwaite & Ito, Compilation, alignment, and phylogenetic relationships of DNA polymerases, Nucl. Acids Res. 21:787 802 (1993). * |
Chien et al., "Deoxyribonucleic Acid Polymerase from the Extreme Thermophile Thermus aquaticus," J. Bacteriol. 127:1550-1557 (Sep. 1976). |
Chien et al., Deoxyribonucleic Acid Polymerase from the Extreme Thermophile Thermus aquaticus, J. Bacteriol. 127:1550 1557 (Sep. 1976). * |
Cowan et al., "An extremely thermostable extracellular proteinase from a strain of the archaebacterium Desulfurococcus growing at 88° C.," J. Biochem. 274:121-133 (1987). |
Cowan et al., An extremely thermostable extracellular proteinase from a strain of the archaebacterium Desulfurococcus growing at 88 C., J. Biochem. 274:121 133 (1987). * |
Elie et al., "Thermostable DNA polymerase from the archaebacterium Sulfolobus acidocaldarius: Purification, characterization and immunological properties," Eur. J. Biochem. 178:619-626 (1989). |
Elie et al., Thermostable DNA polymerase from the archaebacterium Sulfolobus acidocaldarius: Purification, characterization and immunological properties, Eur. J. Biochem. 178:619 626 (1989). * |
Gelfand & White, "Thermostable DNA Polymerases," in: PCR Protocols: A Guide to Methods and Applications, Innis et al. (eds.) Academic Press, Inc., San Diego, CA, pp. 129-130 (1990). |
Gelfand & White, Thermostable DNA Polymerases, in: PCR Protocols: A Guide to Methods and Applications, Innis et al. (eds.) Academic Press, Inc., San Diego, CA, pp. 129 130 (1990). * |
Kaboev et al., "Purification and Properties of Deoxyribonucleic Acid Polymerase from Bacillus stearothermophilus," J. Bacteriol. 145:21-26 (Jan. 1981). |
Kaboev et al., Purification and Properties of Deoxyribonucleic Acid Polymerase from Bacillus stearothermophilus, J. Bacteriol. 145:21 26 (Jan. 1981). * |
Kaledin et al., "Isolation and Properties of DNA Polymerase from Extremely Thermophilic Bacterium Thermus aquaticus YT1," Biokhimiya 45:644-651 (Apr. 1980). |
Kaledin et al., Isolation and Properties of DNA Polymerase from Extremely Thermophilic Bacterium Thermus aquaticus YT1, Biokhimiya 45:644 651 (Apr. 1980). * |
Kelly & Deming, "Extremely Thermophilic Archaebacteria: Biological and Engineering Considerations," Biotech. Prog. 4:47-62 (Jun. 1988). |
Kelly & Deming, Extremely Thermophilic Archaebacteria: Biological and Engineering Considerations, Biotech. Prog. 4:47 62 (Jun. 1988). * |
Klimczak et al., "Purification and Characterization of DNA Polymerase from the Archaebacteria Methanobacterium thermoautotrophicum," Biochem. 25:4850-4855 (1986). |
Klimczak et al., Purification and Characterization of DNA Polymerase from the Archaebacteria Methanobacterium thermoautotrophicum, Biochem. 25:4850 4855 (1986). * |
Lin et al., "Cloning and expression of T4 DNA polymerase," Proc. Natl. Acad. Sci. USA 84:7000-7004 (Oct. 1987). |
Lin et al., Cloning and expression of T4 DNA polymerase, Proc. Natl. Acad. Sci. USA 84:7000 7004 (Oct. 1987). * |
Mattila et al., "Fidelity of DNA synthesis by the Thermococcus litoralis DNA polymerase--an extremely heat stable enzyme with proofreading activity," Nucl. Acids Res. 19:4967-4973 (Sep. 25, 1991). |
Mattila et al., Fidelity of DNA synthesis by the Thermococcus litoralis DNA polymerase an extremely heat stable enzyme with proofreading activity, Nucl. Acids Res. 19:4967 4973 (Sep. 25, 1991). * |
Minkley et al., "Escherichia coli DNA Polymerase I," J. Biol. Chem. 259:10386-10392 (Aug. 25, 1984). |
Minkley et al., Escherichia coli DNA Polymerase I, J. Biol. Chem. 259:10386 10392 (Aug. 25, 1984). * |
Patel et al., "Isolation of anaerobic, extremely thermophilic, sulphur metabolising archaebacteria from New Zealand hot springs," New Zealand J. Marine & Freshwater Res. 20:439-445 (1986). |
Patel et al., Isolation of anaerobic, extremely thermophilic, sulphur metabolising archaebacteria from New Zealand hot springs, New Zealand J. Marine & Freshwater Res. 20:439 445 (1986). * |
Reddy et al., "Hyperexpression and purification of Escherichia coli adenylate cyclase using a vector designed for expression of lethal gene products," Nucl. Acids Res. 17:10473-10488 (1989). |
Reddy et al., Hyperexpression and purification of Escherichia coli adenylate cyclase using a vector designed for expression of lethal gene products, Nucl. Acids Res. 17:10473 10488 (1989). * |
Rossi et al., "Structure and Properties of a Thermophilic and Thermostable DNA Polymerase Isolated from Sulfolobus solfataricus," System. Appl. Microbiol. 7:337-341 (1986). |
Rossi et al., Structure and Properties of a Thermophilic and Thermostable DNA Polymerase Isolated from Sulfolobus solfataricus, System. Appl. Microbiol. 7:337 341 (1986). * |
Simpson et al., "Purification and some properties of a thermostable DNA polymerase from a Thermotoga species," Biochem. Cell Biol. 68:1292-1296 (1990). |
Simpson et al., Purification and some properties of a thermostable DNA polymerase from a Thermotoga species, Biochem. Cell Biol. 68:1292 1296 (1990). * |
Stenesh & Roe, "DNA Polymerases from Mesophilic and Thermophilic Bacteria: Purification and Properties of DNA Polymerase from Bacillus licheniformis and Bacillus stearothermophilus," Biochim. Biophys. Acta 272:156-166 (19872). |
Stenesh & Roe, DNA Polymerases from Mesophilic and Thermophilic Bacteria: Purification and Properties of DNA Polymerase from Bacillus licheniformis and Bacillus stearothermophilus, Biochim. Biophys. Acta 272:156 166 (19872). * |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5756334A (en) * | 1990-04-26 | 1998-05-26 | New England Biolabs, Inc. | Thermostable DNA polymerase from 9°N-7 and methods for producing the same |
US6015668A (en) * | 1994-09-30 | 2000-01-18 | Life Technologies, Inc. | Cloned DNA polymerases from thermotoga and mutants thereof |
US6444424B1 (en) | 1994-09-30 | 2002-09-03 | Invitrogen Corporation | Cloned DNA polymerases from Thermotoga neapolitana |
US5912155A (en) * | 1994-09-30 | 1999-06-15 | Life Technologies, Inc. | Cloned DNA polymerases from Thermotoga neapolitana |
US5939301A (en) * | 1994-09-30 | 1999-08-17 | Life Technologies, Inc. | Cloned DNA polymerases from Thermotoga neapolitana and mutants thereof |
US20030162201A1 (en) * | 1994-09-30 | 2003-08-28 | Invitrogen Corporation | Cloned DNA polymerases from Thermotoga and mutants thereof |
US5948614A (en) * | 1995-09-08 | 1999-09-07 | Life Technologies, Inc. | Cloned DNA polymerases from thermotoga maritima and mutants thereof |
WO1997009451A1 (en) * | 1995-09-08 | 1997-03-13 | Life Technologies, Inc. | Cloned dna polymerases from thermotoga and mutants thereof |
US7049101B1 (en) | 1997-08-06 | 2006-05-23 | Diversa Corporation | Enzymes having high temperature polymerase activity and methods of use thereof |
US5948666A (en) * | 1997-08-06 | 1999-09-07 | Diversa Corporation | Isolation and identification of polymerases |
US8148126B2 (en) | 1997-08-06 | 2012-04-03 | Verenium Corporation | Polymerase |
US7781198B2 (en) | 1997-08-06 | 2010-08-24 | Verenium Corporation | Polymerase-encoding nucleic acids and method of making and using them |
US7056703B2 (en) | 1997-08-06 | 2006-06-06 | Diversa Corporation | Polypeptides having polymerase activity and methods of use thereof |
WO1999007837A1 (en) * | 1997-08-06 | 1999-02-18 | Diversa, Inc. | Isolation and identification of novel polymerases |
US6492511B2 (en) * | 1997-08-06 | 2002-12-10 | Diversa Corporation | Isolation and identification of novel polymerases |
US6130045A (en) * | 1998-06-11 | 2000-10-10 | Clontech Laboratories, Inc. | Thermostable polymerase |
WO1999064438A1 (en) * | 1998-06-11 | 1999-12-16 | Clontech Laboratories, Inc. | Thermostable polymerase |
US7611869B2 (en) | 2000-02-07 | 2009-11-03 | Illumina, Inc. | Multiplexed methylation detection methods |
US20030170684A1 (en) * | 2000-02-07 | 2003-09-11 | Jian-Bing Fan | Multiplexed methylation detection methods |
US8906626B2 (en) | 2000-02-07 | 2014-12-09 | Illumina, Inc. | Multiplex nucleic acid reactions |
US8288103B2 (en) | 2000-02-07 | 2012-10-16 | Illumina, Inc. | Multiplex nucleic acid reactions |
US8076063B2 (en) | 2000-02-07 | 2011-12-13 | Illumina, Inc. | Multiplexed methylation detection methods |
US20030003490A1 (en) * | 2000-02-07 | 2003-01-02 | Illumina, Inc. | Nucleic acid detection methods using universal priming |
US8003354B2 (en) | 2000-02-07 | 2011-08-23 | Illumina, Inc. | Multiplex nucleic acid reactions |
US6479558B1 (en) | 2000-04-04 | 2002-11-12 | Westinghouse Savannah River Company | Microbial processing of used rubber |
US6420457B1 (en) | 2000-04-04 | 2002-07-16 | Westinghouse Savannah River Company, Llc | Microwave treatment of vulcanized rubber |
US6407144B1 (en) | 2000-04-04 | 2002-06-18 | Westinghouse Savannah River Company, Llc | Combination biological and microwave treatments of used rubber products |
US7955794B2 (en) | 2000-09-21 | 2011-06-07 | Illumina, Inc. | Multiplex nucleic acid reactions |
US7582420B2 (en) | 2001-07-12 | 2009-09-01 | Illumina, Inc. | Multiplex nucleic acid reactions |
US20030143618A1 (en) * | 2002-01-23 | 2003-07-31 | Yves Hatzfield | Method for easy cloning and selection of chimeric DNA molecules |
US6955882B2 (en) * | 2002-01-23 | 2005-10-18 | Cropdesign N.V. | Method for easy cloning and selection of chimeric DNA molecules |
US20040259105A1 (en) * | 2002-10-03 | 2004-12-23 | Jian-Bing Fan | Multiplex nucleic acid analysis using archived or fixed samples |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USH1531H (en) | Thermophilic DNA polymerase | |
US5830714A (en) | Biologically active fragment of bacillus stearothermophilus DNA polymerase | |
US5405774A (en) | DNA encoding a mutated thermostable nucleic acid polymerase enzyme from thermus species sps17 | |
DE69836779T2 (en) | Mutated chimeric DNA polymerases | |
US6280998B1 (en) | Purified thermostable pyrococcus furiosus DNA ligase | |
JP2584198B2 (en) | Gene encoding a thermostable nucleic acid polymerase from Thermotoga maritima | |
US5455170A (en) | Mutated thermostable nucleic acid polymerase enzyme from Thermus species Z05 | |
US5489523A (en) | Exonuclease-deficient thermostable Pyrococcus furiosus DNA polymerase I | |
US6306588B1 (en) | Polymerases for analyzing or typing polymorphic nucleic acid fragments and uses thereof | |
RU2238978C2 (en) | Recombinant thermostable dna polymerase, method for its preparing and application | |
JP3761197B2 (en) | New DNA polymerase | |
JP2582980B2 (en) | Purified thermostable nucleic acid polymerase from Agrobacterium guinea pig | |
JP3626226B2 (en) | Thermostable nucleic acid polymerase | |
US20070020622A1 (en) | DNA Polymerases and mutants thereof | |
WO1998035060A9 (en) | Polymerases for analyzing or typing polymorphic nucleic acid fragments and uses thereof | |
JPH09511643A (en) | Purified DNA polymerase from Bacillus stearothermophilus | |
JP3742659B2 (en) | DNA polymerase-related factors | |
US5510473A (en) | Cloning of the recA gene from thermus aquaticus YT-1 | |
EP0547359B1 (en) | Purified thermostable dna polymerase obtainable from pyrococcus species | |
CA2294646A1 (en) | Human catalytic telomerase sub-unit and its diagnostic and therapeutic use | |
EP1466013A2 (en) | Thermus scotoductus nucleic acid polymerases | |
EP0960201A1 (en) | Mammalian ribonuclease inhibitors and use thereof | |
Watillon et al. | Cloning and characterization of an apple (Malus domestica (L.) Borkh) cDNA encoding a calmodulin-binding protein domain similar to the calmodulin-binding region of type II mammalian Ca2+/calmodulin-dependent protein kinase | |
JP3498808B2 (en) | DNA polymerase gene | |
JPH11151087A (en) | Dna polymerase gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: LIFE TECHNOLOGIES, INC., MARYLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BLUMENTALS, ILSE I.;LASKEN, ROGER S.;SCHMIDT, BRIAN J.;AND OTHERS;REEL/FRAME:007026/0748 Effective date: 19940415 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: BANK OF AMERICA, N.A., AS COLLATERAL AGENT, WASHIN Free format text: SECURITY AGREEMENT;ASSIGNOR:LIFE TECHNOLOGIES CORPORATION;REEL/FRAME:021975/0467 Effective date: 20081121 |
|
AS | Assignment |
Owner name: LIFE TECHNOLOGIES CORPORATION, CALIFORNIA Free format text: LIEN RELEASE;ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:030182/0461 Effective date: 20100528 |
|
AS | Assignment |
Owner name: INVITROGEN CORPORATION, CALIFORNIA Free format text: MERGER;ASSIGNOR:LIFE TECHNOLOGIES, INC.;REEL/FRAME:031906/0503 Effective date: 20000913 Owner name: LIFE TECHNOLOGIES CORPORATION, CALIFORNIA Free format text: MERGER;ASSIGNOR:LT NAME CORPORATION;REEL/FRAME:031906/0718 Effective date: 20081121 Owner name: INVITROGEN CORPORATION, CALIFORNIA Free format text: MERGER;ASSIGNOR:LT NAME CORPORATION;REEL/FRAME:031906/0718 Effective date: 20081121 |